<SEC-DOCUMENT>0000950157-22-001253.txt : 20221129
<SEC-HEADER>0000950157-22-001253.hdr.sgml : 20221129
<ACCEPTANCE-DATETIME>20221129082944
ACCESSION NUMBER:		0000950157-22-001253
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221128
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221129
DATE AS OF CHANGE:		20221129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Viatris Inc
		CENTRAL INDEX KEY:			0001792044
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				834364296
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39695
		FILM NUMBER:		221428541

	BUSINESS ADDRESS:	
		STREET 1:		1000 MYLAN BOULEVARD
		CITY:			CANONSBURG
		STATE:			PA
		ZIP:			15317
		BUSINESS PHONE:		(724) 514-1465

	MAIL ADDRESS:	
		STREET 1:		1000 MYLAN BOULEVARD
		CITY:			CANONSBURG
		STATE:			PA
		ZIP:			15317

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Upjohn Inc
		DATE OF NAME CHANGE:	20191023
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:vtrs="http://viatris.com/20221128" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Cravath, Swaine & Moore LLP
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_e5d797da3d57472ba710ea0d5b8747c4" contextRef="c20221128to20221128" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_68740d7e391e48c88f29d1ccc03be8c7" contextRef="c20221128to20221128">0001792044</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="vtrs-20221128.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20221128to20221128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001792044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-28</xbrli:startDate><xbrli:endDate>2022-11-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div><br />
    </div>

    <div>
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div><br /></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

    <div><br />
    </div>

    <div>
      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div><br />
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_6e1c3a5d83c24a4fba3e23f8cf8407b6" contextRef="c20221128to20221128">8-K</ix:nonNumeric></div>

    <div><br />
    </div>

    <div>
      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section&#160;13 or 15(d)</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">of the Securities Exchange Act of 1934</div>

    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported):&#160; <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_3a032140668947acbcd9f3092fe10e5d" contextRef="c20221128to20221128" format="ixt:datemonthdayyearen">November 28, 2022</ix:nonNumeric></div>

    <div><br />
    </div>

    <div>
      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-style: normal; font-variant: normal; text-transform: uppercase;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_b58e9d79181d436c81c47605852b3cb6" contextRef="c20221128to20221128">Viatris Inc</ix:nonNumeric></span>.</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>

    <div><br />
    </div>

    <div>
      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_085cc3bf6e7c4115b4f7f88d510664cd" contextRef="c20221128to20221128" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: middle;">&#160;</td>

    <td style="width: 32%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_013104b11bbe4c22b5be685dbb6c6e84" contextRef="c20221128to20221128">001-39695</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: middle;">&#160;</td>

    <td style="width: 32%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_6e2ce73ca0c84a5db4f78eb363b265c9" contextRef="c20221128to20221128">83-4364296</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: bold;">(<span style="font-size: 8pt; font-family: 'Times New Roman'; color: #000000;">State or Other Jurisdiction</span></div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: bold;"><span style="font-size: 8pt; font-family: 'Times New Roman'; color: #000000;">of Incorporation</span>)</div>
          </td>

    <td style="width: 2%; vertical-align: middle;">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: bold;">(Commission</div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: bold;">File Number)</div>
          </td>

    <td style="width: 2%; vertical-align: middle;">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: bold;">(<span style="font-size: 8pt; font-family: 'Times New Roman'; color: #000000;">I.R.S. Employer</span></div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: bold;"><span style="font-size: 8pt; font-family: 'Times New Roman'; color: #000000;">Identification No.</span>)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: middle;">&#160;</td>

    <td style="width: 2%; vertical-align: middle;">&#160;</td>

    <td style="width: 32%; vertical-align: middle;">&#160;</td>

    <td style="width: 2%; vertical-align: middle;">&#160;</td>

    <td style="width: 32%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td colspan="5" style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_72b50815798848f58c7d97cf397f8480" contextRef="c20221128to20221128">1000 Mylan Boulevard</ix:nonNumeric>,&#160;</span><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_f9329242c5cf42b88f942f207f89ae20" contextRef="c20221128to20221128">Canonsburg</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_031e1e52ec634a0c8a23b1179a1a5644" contextRef="c20221128to20221128" format="ixt-sec:stateprovnameen">Pennsylvania</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_37f62a3a82484ab8aae7871945ee2317" contextRef="c20221128to20221128">15317</ix:nonNumeric></div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 8pt; font-weight: bold;">&#160;(Address of Principal Executive Offices)</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric name="dei:CityAreaCode" id="Fact_30e620a1e64d4822b525a13f6654b064" contextRef="c20221128to20221128">724</ix:nonNumeric>)
      <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_cdaa16584b8f4eea95f716bdd230c982" contextRef="c20221128to20221128">514-1800</ix:nonNumeric></div>

    <div><br />
    </div>

    <div>
      <hr style="height: 2px; width: 15%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">see</span> General Instruction A.2. below):</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="2" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 5%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_6c3105f683394a4d98b5a86d5ec7fc41" contextRef="c20221128to20221128" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 95%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_abaa83f172c340deb4d5e9cba6d41bb0" contextRef="c20221128to20221128" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 95%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_14858c59b469400d9fb3ee99d3eaf108" contextRef="c20221128to20221128" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 95%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_cc296257a6ba405992e7289f3aa40b4a" contextRef="c20221128to20221128" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 95%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36.77%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 1.2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 30.41%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Trading</div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Symbol(s)</div>
          </td>

    <td style="width: 1.2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 30.42%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Name of each exchange</div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 36.77%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_e5cc3d5e7f2d42aba75eb3aca7a8487f" contextRef="c20221128to20221128">Common Stock, par value $0.01 per share</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 1.2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 30.41%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_b2417f93aefb45baa106a0acf3a57dee" contextRef="c20221128to20221128">VTRS</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 1.2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 30.42%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_bb49caa5b7964fef9244ba5a01bcd9a4" contextRef="c20221128to20221128" format="ixt-sec:exchnameen">The NASDAQ Stock Market</ix:nonNumeric><br />
            </div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2
      of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</div>

    <div><br />
    </div>

    <div style="text-align: right; text-indent: 36pt; margin-left: 360pt; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_4c1970b874a84c1a86695eaf76bfb80a" contextRef="c20221128to20221128" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
      financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-size: 10pt; font-family: 'Times New Roman';">&#9744;</span></div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
      </span></div>

    <div><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
    </span></div>

    <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
      </span></div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;" /></div>

    </div>

    <div><br />
    </div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item&#160;1.01</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Entry into a Material Definitive Agreement.</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">On November 29, 2022, Viatris Inc., a Delaware corporation (&#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Viatris</span></span>&#8221;),
      announced that it closed the previously announced&#160; transaction with Biocon Biologics Limited, a public limited company incorporated under the India Companies Act, 2013 (&#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Biocon
          Biologics</span></span>&#8221;), involving the transfer by Viatris of substantially all of its biosimilars portfolio (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Biosimilars Business</span></span>&#8221;) to Biocon Biologics and its
      subsidiaries (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Transaction</span></span>&#8221;) in exchange for consideration from Biocon Biologics and its subsidiaries of $3.335 billion on a cash-free, debt-free basis, consisting of
      (a) $2.0 billion in cash consideration at closing, subject to certain adjustments as set forth in the Transaction Agreement (as defined below), (b) a convertible preferred equity stake in Biocon Biologics initially representing 12.9% of the equity in
      Biocon Biologics (on a fully diluted basis), which the parties&#8217; valued at $1 billion in the Transaction, (c) $160.0 million in future cash consideration, payable on the second anniversary of closing and (d) $175.0 million in future cash
      consideration, payable on April 8, 2024 (as a result of Biocon Biologics not exercising its right to exclude certain assets and liabilities related to Viatris&#8217; aflibercept product candidate from the Transaction).&#160; Approximately $150 million of the
      closing cash consideration was financed by equity commitments from Serum Institute Life Sciences Private Limited and approximately $650 million of the closing cash consideration was financed by equity commitments from Biocon Limited and its
      affiliate, Biocon Pharma Limited.&#160; The consideration is subject to certain post-closing adjustments and indemnities as set forth in the Transaction Agreement.</div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">On November 28, 2022, prior to the closing of the Transaction, Viatris and Biocon Biologics entered into Amendment No. 1 (&#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Amendment No. 1</span></span>&#8221;) to the Transaction Agreement, dated as of February 27, 2022, between Viatris and Biocon Biologics (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Original







          Transaction Agreement</span></span>&#8221; and, as amended by Amendment No. 1, the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Transaction Agreement</span></span>&#8221;).&#160; Amendment No. 1, among other things, (a) modified certain aspects of
      the structuring of the Transaction, (b) modified the timing and procedures for determining the purchase price adjustments, including relating to working capital, and (c) increased the amount of the working capital target from $150 million to $225
      million.&#160; In addition, pursuant to the Transaction Agreement, at the closing of the Transaction, Viatris retained cash and certain current assets otherwise included in the working capital of the Biosimilars Business in an aggregate amount equal to
      the working capital target.&#160; All or a portion of such amounts may become payable to Biocon Biologics in connection with certain events in the future, depending on the valuations attributable to such events.</div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing description of the Transaction Agreement, and the transactions contemplated thereby, does not purport to be complete and is subject to,
      and qualified in its entirety by reference to, the full text of (i) the Original Transaction Agreement, which is attached as Exhibit 2.1 to Viatris&#8217; Form 8-K filed with the SEC on February 28, 2022 and incorporated herein by reference, and (ii)
      Amendment No. 1, which is attached as Exhibit 2.1 hereto and incorporated herein by reference.</div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The above description of the Transaction Agreement has been included to provide investors and security holders with information regarding the terms of
      such agreements.&#160; It is not intended to provide any other factual information about Viatris and Biocon Biologics and their respective subsidiaries and affiliates, or any of their respective businesses.&#160; The Transaction Agreement contains
      representations and warranties that are solely for the benefit of parties thereto.&#160; The assertions embodied in those representations and warranties are qualified by information in confidential disclosure letters that the parties have exchanged in
      connection with signing the Transaction Agreement as of a specific date.&#160; The disclosure letters contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Transaction Agreement.&#160;
      Therefore, investors and security holders should not treat the representations and warranties as categorical statements of fact.&#160; Moreover, these representations and warranties may apply standards of materiality in a way that is different from what
      may be material to investors.&#160; They were made only as of the date of the Original Transaction Agreement or such other date or dates as may be specified in the Transaction Agreement and they are subject to more recent developments.&#160; Accordingly,
      investors and security holders should read the representations and warranties in the Transaction Agreement not in isolation but only in conjunction with the other information about Viatris and its respective subsidiaries that the respective companies
      include in reports and statements Viatris files with the SEC.</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item&#160;2.01</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Completion of Acquisition or Disposition of Assets</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.</div>

    <div>
      <div>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item <span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">7.01</span></td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000;">Regulation FD Disclosure</span></div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

      </div>

    </div>

    <div style="text-align: left; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On November 29, 2022, Viatris issued a press release announcing the closing of the Transaction.&#160; A copy of the press release is
      attached hereto as Exhibit 99.1 and is incorporated herein by reference.</div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the
      Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of
      1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</div>

    <div>
      <div><br />
      </div>

    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;" /></div>

    </div>

    <div><br />
    </div>

    <div>
      <div><br />
      </div>

      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Forward-Looking Statements</div>

      <div><br />
      </div>

    </div>

    <div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Current Report on Form 8-K contains &#8220;forward-looking statements&#8221;. These statements are made pursuant to the safe harbor provisions of the
        Private Securities Litigation Reform Act of 1995.&#160; Such forward-looking statements may include, without limitation, statements about the Transaction, including statements about the future cash consideration payable in the Transaction, the
        post-closing purchase price adjustments and indemnities related to the Transaction, the amounts that may become payable to Biocon Biologics in connection with future events and the sale or conversion of Viatris&#8217; equity stake in Biocon Biologics.
        Forward-looking statements may often be identified by the use of words such as &#8220;will&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;should&#8221;, &#8220;would&#8221;, &#8220;project&#8221;, &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;plan&#8221;, &#8220;estimate&#8221;, &#8220;forecast&#8221;, &#8220;potential&#8221;, &#8220;pipeline&#8221;, &#8220;intend&#8221;, &#8220;continue&#8221;,
        &#8220;target&#8221;, &#8220;seek&#8221; and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking
        statements. Factors that could cause or contribute to such differences include, but are not limited to: the Transaction may not achieve its intended benefits; the parties&#8217; ability to meet expectations regarding the accounting and tax treatments of
        the Transaction; changes in relevant tax and other laws; the possibility that Viatris may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the transaction pursuant to which Mylan N.V. (&#8220;Mylan&#8221;)
        combined with the Pfizer Inc.&#8217;s Upjohn business (the &#8220;Upjohn Business&#8221;) in a Reverse Morris Trust transaction (the &#8220;Combination&#8221;) and Upjohn Inc. became the parent entity of the combined Upjohn Business and Mylan business and was renamed &#8220;Viatris
        Inc.&#8221; or Viatris&#8217; global restructuring program within the expected timeframe or at all; the Transaction and other strategic initiatives, including potential divestitures, may not achieve their intended benefits; operational or financial
        difficulties or losses associated with Viatris&#8217; reliance on agreements with Pfizer in connection with the Combination, including with respect to transition services; the potential impact of public health outbreaks, epidemics and pandemics,
        including the ongoing challenges and uncertainties posed by the COVID-19 pandemic; Viatris&#8217; failure to achieve expected or targeted future financial and operating performance and results; actions and decisions of healthcare and pharmaceutical
        regulators; changes in relevant laws and regulations, including but not limited to changes in tax, healthcare and pharmaceutical laws and regulations globally (including the impact of potential tax reform in the U.S.); the ability to attract and
        retain key personnel; Viatris&#8217; liquidity, capital resources and ability to obtain financing; any regulatory, legal or other impediments to the Viatris&#8217; ability to bring new products to market, including but not limited to &#8220;at-risk launches&#8221;;
        success of clinical trials and the Viatris&#8217; or its partners&#8217; ability to execute on new product opportunities and develop, manufacture and commercialize products; any changes in or difficulties with Viatris&#8217; manufacturing facilities, including with
        respect to inspections, remediation and restructuring activities, supply chain or inventory or the ability to meet anticipated demand; the scope, timing and outcome of any ongoing legal proceedings, including government inquiries or investigations,
        and the impact of any such proceedings on Viatris; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with having significant operations globally; the ability to protect
        intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris&#8217; or its partners&#8217; customer and supplier relationships and customer purchasing patterns, including customer
        loss and business disruption being greater than expected following the Combination; the impacts of competition, including decreases in sales or revenues as a result of the loss of market exclusivity for certain products; changes in the economic and
        financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for Viatris&#8217; products; uncertainties and matters beyond the control of management, including but not limited to general political and
        economic conditions, inflation rates and global exchange rates; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance
        with accounting principles generally accepted in the United States<span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</span>and related standards or on an adjusted basis. For more detailed information on the risks
        and uncertainties associated with Viatris, see the risks described in Part I, Item 1A of Viatris&#8217; Annual Report on Form 10-K for the year ended December 31, 2021, as amended, and our other filings with the SEC. You can access Viatris&#8217; filings with
        the SEC through the SEC website at www.sec.gov or through our website, and Viatris strongly encourages you to do so. Viatris routinely posts information that may be important to investors on our website at investor.viatris.com, and we use this
        website address as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC&#8217;s Regulation Fair Disclosure (Reg FD). The contents of our website are not incorporated into this filing or our
        other filings with the SEC. Viatris undertakes no obligation to update any statements herein for revisions or changes after the date of this filing other than as required by law.</div>

    </div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item&#160;9.01</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 6.5%; vertical-align: bottom; border-bottom: 2px solid black;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit No.</div>
            </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 93%; vertical-align: bottom; border-bottom: 2px solid black;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 6.5%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 93%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 6.5%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><a href="ex2-1.htm">2.1</a></div>
            </td>

    <td style="width: 1%; vertical-align: top;"><br />
            </td>

    <td style="width: 93%; vertical-align: bottom;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="ex2-1.htm">Amendment No. 1 to Transaction Agreement, dated as of
                  November 28, 2022, by and between Biocon Biologics Limited and Viatris Inc.*</a></div>
            </td>

  </tr>

  <tr>

    <td style="width: 6.5%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 1%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 93%; vertical-align: bottom;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 6.5%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><a href="ex99-1.htm">99.1</a></div>
            </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 93%; vertical-align: bottom;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="ex99-1.htm">Viatris press release announcing the closing of the
                  Transaction</a></div>
            </td>

  </tr>

  <tr>

    <td style="width: 6.5%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 93%; vertical-align: bottom;">&#160;</td>

  </tr>


</table>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 22.5pt; vertical-align: top; align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">*</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K.&#160; Viatris agrees to furnish supplementally a copy of any omitted
                attachment to the SEC on a confidential basis upon request.</div>
            </td>

  </tr>


</table>
    </div>

    <div><br />
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;" /></div>

    </div>

    <div><br />
    </div>

    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
      authorized.</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
      <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; border-collapse: separate; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" colspan="3">Viatris Inc.</td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 3%;">&#160;</td>

    <td valign="top" colspan="2">&#160;</td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" align="left" style="width: 50%; padding-bottom: 2px;">
              <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left;"><br />
              </div>
            </td>

    <td valign="top" style="width: 3%; padding-bottom: 2px;">
              <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left;">By: </div>
            </td>

    <td valign="top" align="left" style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">/s/ Sanjeev Narula </td>

    <td valign="top" style="width: 12%; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 3%;">&#160;</td>

    <td valign="bottom" align="left" style="width: 4%; white-space: nowrap;">Name:</td>

    <td valign="bottom" align="left" style="width: 31%; white-space: nowrap;">&#160;Sanjeev Narula</td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 3%;">&#160;</td>

    <td valign="top" style="width: 4%;">Title:</td>

    <td valign="top" style="width: 31%;">&#160;Chief Financial Officer</td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 3%;">&#160;</td>

    <td valign="top" colspan="2">&#160;</td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>


</table>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Date: November 29, 2022</div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ex2-1.htm
<DESCRIPTION>AMENDMENT NO. 1 TO TRANSACTION AGREEMENT
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Cravath, Swaine & Moore LLP
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 2.1</font><br>
  </div>
  <div><br>
  </div>
  <div>
    <div style="text-align: center; font-weight: bold;">AMENDMENT NO. 1</div>
    <div style="text-align: center; font-weight: bold;">TO</div>
    <div style="text-align: center; font-weight: bold;">TRANSACTION AGREEMENT</div>
    <div><br>
    </div>
    <div style="text-align: right;">November 28, 2022</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Reference is hereby made to that certain Transaction Agreement, dated as of February 27, 2022 (as amended from time to time, the &#8220;<u>Agreement</u>&#8221;), by and between Biocon Biologics Limited, a public
      limited company incorporated under the Indian Companies Act, 2013 (&#8220;<u>Buyer</u>&#8221;), and Viatris Inc., a Delaware corporation (&#8220;<u>Seller Parent</u>&#8221;). Capitalized terms used but not defined in this Amendment No. 1 to the Transaction Agreement (this &#8220;<u>Amendment</u>&#8221;)


      shall have the respective meanings assigned to them in the Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">WHEREAS, concurrently with the execution and delivery of this Amendment, the Parties are entering into Amendment No. 1 to the Seller Parent Disclosure Letter; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">WHEREAS, the Parties desire to amend the Agreement in accordance with the terms set forth herein.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">NOW, THEREFORE, in consideration of the premises and the representations, warranties, covenants and agreements contained in this Amendment and the Agreement, and subject to the conditions set forth
      herein and therein, the Parties hereby agree as follows:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zadf2be3a838f4eb5beef44400f41bdb2">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><u>Amendments of the Agreement</u>.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The third recital of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;WHEREAS, prior to the date of this Agreement (a) Mylan Ireland Limited, an Irish private limited company and a Subsidiary of Seller Parent (&#8220;<u>Mylan Ireland</u>&#8221;), transferred its biosimilars
      trade (including Transferred Assets and Assumed Liabilities) to Biosimilar Collaborations Ireland Limited, an Irish private limited company (such transfer, the &#8220;<u>Irish Spin-Off</u>&#8221; and, such transferee, the &#8220;<u>Irish Acquired Company</u>&#8221;) and (b)
      Mylan Ireland transferred all of the issued and outstanding equity interests in the Irish Acquired Company to the Irish Seller and, as of the date of this Agreement, the Irish Seller is the sole record and beneficial owner of all of the issued and
      outstanding equity interests (including any preference shares) in the Irish Acquired Company;&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The seventh recital of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;WHEREAS, Buyer is the sole record and beneficial owner of all of the issued and outstanding equity interests in the Subsidiary Buyer;&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The eighth recital of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div style="text-align: justify; margin-left: 72pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;WHEREAS, upon the terms and subject to the conditions set forth in this Agreement, Seller Parent and Buyer desire to cause (a) the sale of the Acquired ROW Equity Interests from ROW Seller to Buyer
      in exchange for the Stock Consideration, (b) the payment of other amounts as described herein, including, pursuant to the ROW Acquisition, the Irish Future Cash Payment, and (c) (i) the subscription by the Subsidiary Buyer for, and the allotment and
      issue by the Irish Acquired Company of, the Irish New Equity Interests in exchange for the Irish Closing Cash Consideration and (ii) the redemption by the Irish Acquired Company of the Irish Redemption Equity Interests in exchange for an amount equal
      to the Irish Closing Cash Consideration;&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The ninth recital of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;WHEREAS, concurrently with the execution of this Agreement, as an inducement to and condition of Seller Parent&#8217;s willingness to enter into this Agreement and the other Transaction Documents to
      which it is a party, (a) Buyer Parent, Buyer and Seller Parent have duly executed and delivered the Equity Financing Letter, attached as <u>Exhibit I-A</u> hereto (the &#8220;<u>Buyer Parent Equity Financing Letter</u>&#8221;) and (b) Serum, Buyer and Seller
      Parent have duly executed and delivered the Equity Financing Letter, attached as <u>Exhibit I-B</u> hereto (the &#8220;<u>Serum Equity Financing Letter</u>&#8221; and, together with the Buyer Parent Equity Financing Letter, the &#8220;<u>Equity Financing Letters</u>&#8221;);&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Agreement is amended by adding the following as a new recital, immediately after the ninth recital of the Agreement:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;WHEREAS, prior to or concurrently with the execution of this Amendment, as an inducement to and condition of Seller Parent&#8217;s willingness to enter into this Amendment and the other Transaction
      Documents to which it is a party, (a) Buyer Parent, Buyer, BPL and Seller Parent have duly executed and delivered the Amendment to Equity Financing Letter, attached as <u>Exhibit I-C</u> hereto (the &#8220;<u>Buyer Parent Equity Financing Letter Amendment</u>&#8221;;


      the Buyer Parent Equity Financing Letter, as amended by the Buyer Parent Equity Financing Letter Amendment, the &#8220;<u>Buyer Parent Amended Equity Financing Letter</u>&#8221;), and pursuant to the Buyer Parent Amended Equity Financing Letter, upon the terms
      and subject to the conditions set forth therein, prior to the Closing, Buyer Parent, BPL and Buyer shall consummate the Buyer Parent Equity Financing and (b) Serum, Buyer and Seller Parent have duly executed and delivered the Amendment to Equity
      Financing Letter, attached as <u>Exhibit I-D</u> hereto (the &#8220;<u>Serum Equity Financing Letter Amendment</u>&#8221;; the Serum Equity Financing Letter, as amended by the Serum Equity Financing Letter Amendment, the &#8220;<u>Serum Amended Equity Financing
        Letter</u>&#8221; and, the Serum Amended Equity Financing Letter together with the Buyer Parent Amended Equity</div>
    <div style="text-align: justify; margin-left: 108pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">Financing Letter, the &#8220;<u>Amended Equity Financing Letters</u>&#8221;), and pursuant to the Serum Amended Equity Financing Letter, upon the terms and subject to the conditions set forth therein, prior to
      the Closing, Serum and Buyer shall consummate the Serum Equity Financing;&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(f)&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; The first sentence of Section 1.01 of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Closing</u>. The closing of (a) the ROW Acquisition, (b) the repayment in full the ROW Note, (c) the Irish Subscription and (d) the Irish Redemption (the &#8220;<u>Closing</u>&#8221;) shall take place
      remotely via the electronic exchange of documents and signature pages at 10:00 a.m., New York City time, on the second (2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup>) Business Day following the date of
      satisfaction (or, to the extent permitted by Law, waiver by the Parties entitled to the benefit thereof) of all of the conditions set forth in <u>Article VI</u> (other than those conditions which by their terms are to be satisfied at the Closing,
      but subject to satisfaction or waiver of such conditions), or at such other place, time and date as shall be agreed in writing between Buyer and Seller Parent.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 1.02(a) of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>ROW Acquisition</u>.&#160; Seller Parent shall cause the ROW Seller to sell, assign, transfer, convey and deliver to Buyer, and Buyer shall purchase and accept from the ROW Seller, the Acquired ROW
      Equity Interests, in each case, in accordance with <u>Section 1.03</u> and <u>Section 1.04</u> (the &#8220;<u>ROW Acquisition</u>&#8221;), free and clear of Liens, other than (A) transfer restrictions under applicable Securities Laws and (B) those arising
      pursuant to this Agreement or from acts of Buyer or its Affiliates (including any Liens related to the Debt Financing). The aggregate consideration payable in respect of the ROW Acquisition shall be the Stock Consideration (payable when and as set
      forth in <u>Section 1.04</u>). In addition, Buyer shall cause the ROW Acquired Company to repay in full the ROW Note and to pay the ROW Future Cash Payment (payable when and as set forth in <u>Section 1.05</u>). Further, pursuant to the ROW
      Acquisition, Buyer shall cause the Subsidiary Buyer to pay the Irish Future Cash Payment (payable when and as set forth in <u>Section 1.05</u><font style="font-style: italic;">&#160;</font>and subject to <u>Section 1.10</u>).&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(h)&#160;&#160;&#160;&#160; &#160; &#160;&#160; The last sentence of Section 1.02(b) of the Agreement is hereby amended by adding the words &#8220;when and&#8221; immediately before the words &#8220;as set forth&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(i)&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; The last sentence of Section 1.02(c) of the Agreement is hereby amended by adding the words &#8220;when and&#8221; immediately before the words &#8220;as set forth&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(j)&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; Section 1.03 of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div style="text-align: justify; margin-left: 72pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Allocation of Cash Consideration and Acquired Equity Interests</u>.&#160; (i) An amount equal to the Irish Closing Cash Consideration shall be paid to the Irish Seller by the Irish Acquired Company
      in consideration for the Irish Redemption, (ii) the Stock Consideration shall be paid to the ROW Seller by Buyer, (iii) the Adjustment Amount shall be paid (A) to the ROW Seller by the ROW Acquired Company or to the Irish Seller by the Subsidiary
      Buyer, as applicable, or (B) by the ROW Seller and the Irish Seller, as applicable, to the ROW Acquired Company or the Subsidiary Buyer, in the case of each of clauses (A) and (B), with the ROW Seller and the Irish Seller receiving or paying, as
      applicable, the portion of the Adjustment Amount related to the ROW Acquired Company and the Irish Acquired Company, respectively, (iv) the ROW Future Cash Payment shall be paid to the ROW Seller by the ROW Acquired Company and (v) the Irish Future
      Cash Payment shall be paid to the Irish Seller by the Subsidiary Buyer, in the case of each of clauses (i) through (v), at such times as specified in this Agreement.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 1.04(a)(i) of the Agreement amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;consummate each Equity Financing in accordance with the Amended Equity Financing Letter for such Equity Financing, and immediately thereafter contribute $800,000,000 (eight hundred million dollars)
      to the Subsidiary Buyer (the &#8220;<u>Subsidiary Buyer Contribution</u>&#8221;);&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 1.04(a)(ii) of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;(A) pursuant to the ROW Acquisition convey and deliver to the ROW Seller book-entry interests representing the Stock Consideration, together with duly executed instruments of issuance, sale and
      delivery in respect thereof, in form and substance reasonably acceptable to Seller Parent, evidencing the issuance, sale and delivery of the Stock Consideration, (B) immediately after the conveyance and delivery to Buyer of duly executed instruments
      of assignment in respect of the Acquired ROW Equity Interests pursuant to <u>Section 1.04(b)(i)</u>, cause the Subsidiary Buyer to pay, or to cause to be paid (out of the proceeds of the Subsidiary Buyer Contribution), to the ROW Acquired Company,
      by wire transfer of immediately available funds to the account(s) designated in writing by Buyer (such designation to be set forth in the ROW Letter of Direction), an amount equal to $212,000,000 (two hundred twelve million dollars), in exchange for
      the ROW Acquired Company allotting and issuing to Subsidiary Buyer new ordinary shares or preference shares of the ROW Acquired Company (the &#8220;<u>Buyer ROW Contribution</u>&#8221;), and (C) immediately after the Buyer ROW Contribution, cause the ROW
      Acquired Company to pay (which payment shall be in part out of the proceeds of the Buyer ROW Contribution), to the</div>
    <div style="text-align: justify; margin-left: 108pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">ROW Seller, by wire transfer of immediately available funds to the account(s) designated in writing by Seller Parent (such designation to be set forth in the ROW Letter of Direction), an amount
      equal to the amount required to repay in full the ROW Note;&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 1.04(a)(iii) of the Agreement is hereby amended by replacing the words &#8220;writing by Seller Parent at least two (2) Business Days prior to the Closing Date&#8221; with the words &#8220;the
      Irish Letter of Direction&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The first sentence of Section 1.04(b) of the Agreement is hereby amended by replacing the words &#8220;upon receipt of the Estimated Closing Cash Consideration and the Stock Consideration&#8221; with
      the words &#8220;upon (x) the substantially concurrent receipt of the Stock Consideration and immediately available funds described in Section 1.04(a)(ii) and (y) the substantially concurrent receipt of the immediately available funds described in Section
      1.04(a)(iii)&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 1.04(b)(i) of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;pursuant to the ROW Acquisition, cause the ROW Seller to convey and deliver to Buyer duly executed instruments of assignment, in form and substance reasonably acceptable to Buyer, evidencing the
      sale, assignment, transfer, conveyance and delivery of the Acquired ROW Equity Interests;&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 1.04(b)(iii) of the Agreement is hereby amended by replacing the words &#8220;writing by Seller Parent at least two (2) Business Days prior to the Closing Date&#8221; with the words &#8220;the
      Irish Letter of Direction&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The heading of Section 1.05 of the Agreement is hereby amended by replacing the words &#8220;Future Cash Consideration&#8221; with the words &#8220;Future Cash Payments&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 1.05(a) of the Agreement is hereby amended by deleting the phrase &#8220;(or, at Seller Parent&#8217;s election, any other wholly owned Subsidiary of Seller Parent as may be designated in
      writing by Seller Parent at least two (2) Business Days prior to April 8, 2024)&#8221; from the first sentence thereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 1.05(b) of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;If the Closing occurs, then, subject to <u>Section 8.09</u>, within two (2) Business Days following the Second Anniversary Date, Buyer shall take all actions to cause the ROW Acquired Company to
      pay to the ROW Seller, by wire transfer of immediately available funds to the account(s) designated in writing by Seller Parent at least two (2) Business Days prior to the Second Anniversary Date, an amount equal to $160,000,000 (one hundred sixty</div>
    <div style="text-align: justify; margin-left: 108pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">million dollars) (the &#8220;<u>ROW Future Cash Payment</u>&#8221; and, together with the Irish Future Cash Payment, the &#8220;<u>Future Cash Payments</u>&#8221;).&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(t)&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; The heading of Section 1.06 of the Agreement is hereby amended by replacing the words &#8220;Purchase Price Adjustment&#8221; with the words &#8220;Adjustment Amounts&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 1.06 of the Agreement is hereby amended by replacing each reference to &#8220;Final Closing Cash Consideration&#8221; with a reference to &#8220;Final Adjustment Amount&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 1.06(a) of the Agreement is hereby amended by (i) replacing the words &#8220;Not less than five (5) Business Days prior to the Closing Date,&#8221; with the words &#8220;Within five (5) Business
      Days after the Closing Date,&#8221; and (ii) replacing the words &#8220;Estimated Closing Cash Consideration&#8221; with the words &#8220;Estimated Adjustment Amount&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(w)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 1.06(b) of the Agreement is hereby amended by replacing the words &#8220;forty-five (45)&#8221; with the words &#8220;sixty (60)&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 1.07(a) of the Agreement is hereby amended by replacing the word &#8220;Sellers&#8221; with the words &#8220;Irish Seller and the ROW Acquired Company to pay to the ROW Seller, as applicable&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(y)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 1.07(b) of the Agreement is hereby amended by (i) replacing the word &#8220;Sellers&#8221; with the words &#8220;ROW Seller to pay to the ROW Acquired Company and the Irish Seller to pay to the
      Subsidiary Buyer, as applicable&#8221; and (ii) deleting the words &#8220;to pay to the Subsidiary Buyer&#8221; immediately following the parenthetical thereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(z)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 2.03(a) of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;As of immediately prior to the Closing and after giving effect to the Business Internal Reorganization, (i) the ROW Seller will be the sole record and beneficial owner of all of the issued and
      outstanding equity interests in ROW Newco, (ii) the ROW Seller will have good and valid title to all of the Acquired ROW Equity Interests, free and clear of Liens other than (A) transfer restrictions under applicable Securities Laws and (B) those
      arising from acts of Buyer or its Affiliates (including any Liens related to the Debt Financing), and (iii) the ROW Seller will be the record and the beneficial owner of all such Acquired ROW Equity Interests. Assuming Buyer has the requisite power
      and authority to be the lawful owner of the Acquired ROW Equity Interests, upon (i) delivery by the ROW Seller to Buyer at the Closing of the items described in <u>Section&#160;1.04(b)(i)</u> and (ii) delivery by Buyer and the ROW Acquired Company, as
      applicable, to the ROW Seller of the consideration required to be paid by Buyer and the ROW Acquired</div>
    <div style="text-align: justify; margin-left: 108pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">Company at the Closing, as described in <u>Section 1.04(a)(ii)</u>, good and valid title to the Acquired ROW Equity Interests will pass to Buyer at the Closing, free and clear of Liens, other than
      (i) transfer restrictions under applicable Securities Laws and (ii) those arising pursuant to this Agreement or from acts of Buyer or its Affiliates (including any Liens related to the Debt Financing), and the Acquired ROW Equity Interests, together
      with the equity interests in the ROW Acquired Company to be issued to the Subsidiary Buyer in the Buyer ROW Contribution, will constitute 100% of the issued share capital of the ROW Acquired Company immediately following the Closing. Upon issuance,
      each Acquired ROW Equity Interest will be (in each case, to the extent such concepts are applicable) duly authorized, validly issued, fully paid and nonassessable, and will not be issued or transferred in violation of any purchase option, call
      option, right of first refusal, preemptive right, subscription right or other similar right under any provision of the Applicable Business Organization Law or the organizational or similar documents of Seller Parent or any of its Subsidiaries
      (including the ROW Seller and the ROW Acquired Company).&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(aa)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 3.01 of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each of Buyer and its Subsidiaries (i)&#160;is duly organized, validly existing and in good standing (with respect to jurisdictions that recognize such concept) under the Applicable
      Business Organization Law, (ii)&#160;has full corporate or similar power and authority to own, lease or license, and to operate, its properties and assets and to operate its business as currently operated and (iii)&#160;is duly qualified or licensed to do
      business as a foreign company and in good standing (with respect to jurisdictions that recognize such concept) in each jurisdiction where the character of the properties owned, leased or operated by it or the nature of its business makes such
      qualification or licensing necessary, in the case of each of clauses (i), (ii) and (iii), in all material respects.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;True, correct and complete copies of the organizational or similar documents of Buyer and each of its Subsidiaries, as in effect on the date of this Agreement, have been made available
      to Seller Parent. Each such organizational or similar document is in full force and effect in all material respects, and none of Buyer or its Subsidiaries is in material violation of any provisions thereof.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(bb)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 3.02(a) of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;Buyer has all necessary corporate or similar power and authority to execute and deliver this Agreement, each of Buyer and Subsidiary Buyer has all necessary corporate or similar power and authority
      to execute and deliver</div>
    <div style="text-align: justify; margin-left: 108pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">any other Transaction Document to which it is, or is specified to be, a party, and to perform its obligations hereunder and thereunder and to consummate the Transactions to be consummated by it.
      Without limiting the generality of the foregoing, each of Buyer and Subsidiary Buyer has all necessary corporate or similar power and authority to cause each of its Subsidiaries (including, at and following such time as they become Subsidiaries of
      Buyer, the Business Companies) to perform the respective obligations under this Agreement and the other Transaction Documents required to be performed by such Subsidiaries and to consummate the Transactions to be consummated by such Subsidiaries (in
      the case of the Business Companies, at and following such time as they become Subsidiaries of Buyer). The execution, delivery and performance by Buyer of this Agreement, and the execution, delivery and performance by each of Buyer and Subsidiary
      Buyer of any other Transaction Document to which it is, or is specified to be, a party, and the consummation of the Transactions to be consummated by it, have been duly authorized by all necessary corporate or similar action by Buyer and Subsidiary
      Buyer, as applicable. This Agreement has been, and each other Transaction Document to which Buyer or Subsidiary Buyer is, or is specified to be, a party will, at or prior to the Closing, be, duly executed and delivered by Buyer and Subsidiary Buyer,
      as applicable.&#160; Assuming the due authorization, execution and delivery by the other parties thereto, this Agreement constitutes, and each other Transaction Document to which Buyer or Subsidiary Buyer is, or is specified to be, a party will
      constitute, a legal, valid and binding obligation of Buyer and such Subsidiary Buyer, as applicable, enforceable against Buyer and such Subsidiary Buyer, as applicable, in accordance with its terms, except as enforcement thereof may be limited by the
      Enforceability Exceptions.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(cc)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 3.03(a) of the Agreement is hereby amended by (i) replacing the reference to &#8220;<u>Section 1.04(a)(ii)(B)</u>&#8221; with the reference &#8220;<u>Section 1.04(a)(ii)(A)</u>&#8221; and (ii) replacing
      the words &#8220;the Applicable Buyers&#8221; with the word &#8220;Buyer&#8221;, in each case, in the first sentence thereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(dd)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 3.03(c) of the Agreement is hereby amended by replacing the words &#8220;From and after its formation until the Closing, Buyer will be&#8221; in the last sentence thereof with the words
      &#8220;Buyer is&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(ee)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 3.03(d) of the Agreement is hereby amended by replacing the words &#8220;Buyer Parent Equity Financing Letter&#8221; with the words &#8220;Buyer Parent Amended Equity Financing Letter&#8221; in the
      first sentence thereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(ff)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 3.04(a) of the Agreement is hereby amended by deleting the phrase &#8220;(or, in the case of Subsidiary Buyer, following its formation will be)&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(gg)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 3.21(a) of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div style="text-align: justify; margin-left: 72pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">8</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;As of the date of this Agreement, (i) each of the Equity Financing Letters has not been amended, supplemented or modified, and no such amendment, supplement or modification is contemplated, and
      (ii) the covenants and agreements contained in each of the Equity Financing Letters have not been withdrawn, terminated or rescinded in any respect, and no such withdrawal, termination or rescission is contemplated. As of the date of this Amendment,
      (i) each of the Amended Equity Financing Letters has not been amended, supplemented or modified, and no such amendment, supplement or modification is contemplated, and (ii) the covenants and agreements contained in each of the Amended Equity
      Financing Letters have not been withdrawn, terminated or rescinded in any respect, and no such withdrawal, termination or rescission is contemplated. Except for the Amended and Restated Governance Documents, any escrow arrangement entered into in
      connection with the Serum Equity Financing or as set forth in <u>Section 3.21(a)</u> of the Buyer Disclosure Letter, there are no side letters, Contracts or other arrangements or understandings related to any Equity Financing or any Amended Equity
      Financing Letter. The execution, delivery and performance of each of the Amended Equity Financing Letters will not (i) conflict with or violate any provision of the organizational or similar documents of Buyer or any of its Subsidiaries, (ii) require
      any Consent of, or Filing with, any Governmental Entity that has not been made or obtained, (iii) conflict with or violate any Order or Law applicable to Buyer or any of its Subsidiaries or by which any property or asset of Buyer or any of its
      Subsidiaries is bound, (iv) require any Consent by any Person that has not been obtained under, result in a breach of, loss of a benefit or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or
      give to others (immediately or with notice or lapse of time or both) any right of termination, amendment, acceleration or cancellation of, any Contract of Buyer or any of its Subsidiaries or (v) result (immediately or with notice or lapse of time or
      both) in the creation of any Lien (other than a Permitted Lien) on any property or asset of Buyer or any of its Subsidiaries, except, in the case of clauses (ii), (iii), (iv) and (v) above, as would not, individually or in the aggregate, reasonably
      be expected to be material to Buyer and its Subsidiaries, taken as a whole.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(hh)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 3.21(b) of the Agreement is hereby amended by replacing each reference to &#8220;Equity Financing Letters&#8221; with a reference to &#8220;Amended Equity Financing Letters&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 3.21(c) of the Agreement is hereby amended by replacing the words &#8220;any adjustment thereto&#8221; with the words &#8220;the Adjustment Amount&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(jj)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 3.21(c)(ii)(A) of the Agreement is hereby amended by replacing the words &#8220;pay the aggregate Estimated Closing Cash Consideration&#8221; with the words &#8220;repay the ROW Note and pay the
      Irish Closing Cash Consideration&#8221;.</div>
    <div style="text-align: justify; margin-left: 72pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">9</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(kk)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 4.02(b)(i)(a)(1) of the Agreement is hereby amended by replacing the reference to &#8220;Equity Financing Letter&#8221; with a reference to &#8220;Amended Equity Financing Letter&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(ll)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 5.03 of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;SECTION 5.03. <u>Business Internal Reorganization</u><font style="color: #000000;">.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior to the Closing, subject to <u>Section 1.09</u>, Seller Parent shall, and shall cause its Subsidiaries to, consummate the transactions as described in the Business Steps Plan (the
      &#8220;<u>Business Internal Reorganization</u>&#8221;), which Business Internal Reorganization will result in, among other things, the biosimilars business not already held by the Irish Acquired Company (which business consists solely of Transferred Assets and
      Assumed Liabilities not already held by the Irish Acquired Company) being transferred to and assumed by the ROW Acquired Company immediately prior to the Closing. Seller Parent shall provide Buyer with a reasonable opportunity to review and comment
      on the material operative documentation effecting the Business Internal Reorganization and shall accept reasonable comments of Buyer that will not prevent or impede the Intended Tax Treatment. Except as otherwise expressly provided by <u>Section
        1.09</u>, Seller Parent shall be permitted to amend the Business Steps Plan only (i) with the prior written consent of Buyer (such consent not to be unreasonably withheld, delayed or conditioned), (ii) if Seller Parent reasonably determines that
      such amendment is necessary or appropriate to achieve the Intended Tax Treatment or achieve a tax efficient structure for Seller Parent or its Affiliates (<u>provided</u> that any such amendment shall not impose any material costs or expenses on
      Buyer or any Business Company (unless Seller Parent agrees to indemnify and hold harmless Buyer or the applicable Business Company for any such costs or expenses) or materially impair or delay the consummation of the transactions contemplated hereby)
      or (iii) if Seller Parent determines such amendment is reasonably necessary or appropriate to effect the Transactions and such amendment would not reasonably be expected to (A) be material and adverse to Buyer or (B) materially impair or delay the
      consummation of the Transactions.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller Parent shall take all actions required to ensure that, following their formation, the Business Companies are at all times, between the date of this Agreement and the Closing
      Date, Affiliates of the Seller Parent.&#160; Prior to the Closing, Buyer will make the election, with an effective date on or prior to the Closing Date, with respect to the Subsidiary Buyer pursuant to U.S. Treasury Regulation Section 301.7701-3 to treat
      the Subsidiary Buyer as an entity disregarded as separate from its owner for U.S. federal income tax purposes.</div>
    <div style="text-align: justify; margin-left: 108pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">10</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The assignments and transfers of the Business Registered Intellectual Property pursuant to the Business Internal Reorganization shall be recorded and filed by Buyer, with the
      appropriate Governmental Entity following the Closing. Following the Closing, at Buyer&#8217;s reasonable request, Seller Parent shall use reasonable best efforts to provide assistance necessary for Buyer to achieve such recordings and filings. The
      recordation and filing fees pursuant to this <u>Section 5.03(c)</u> shall be borne 50% by Seller Parent and 50% by Buyer.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(mm)&#160;&#160;&#160;&#160;&#160; Section 5.06(a)(iii)(A)(1) of the Agreement is hereby amended by replacing the words &#8220;the ROW Acquisition&#8221; with the words &#8220;the ROW Acquisition, the repayment of the ROW Note, the ROW Future
      Cash Payment&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(nn)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 5.06(c)(ii) of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;From and after the Closing until the date of the payment of the ROW Future Cash Payment, none of Buyer, the Subsidiary Buyer or any of Buyer&#8217;s other Affiliates shall revoke or amend the election
      under Section 301.7701-3 of the U.S. Treasury Regulations or take any other actions to cause the Subsidiary Buyer to be treated as an entity other than an entity disregarded from Buyer (its owner) for U.S. federal income tax purposes (including any
      actions taken after the date of the ROW Future Cash Payment that have a retroactive effect to the date of the ROW Future Cash Payment), without the prior written consent of Seller Parent. From and after the Closing until after the date of the payment
      of the ROW Future Cash Payment, none of Buyer, the Subsidiary Buyer or any of Buyer&#8217;s other Affiliates shall revoke or amend the election under Section 301.7701-3 of the U.S. Treasury Regulations or take any other actions to cause the ROW Acquired
      Company to be treated as an entity other than an entity disregarded from Buyer (its owner) for U.S. federal income tax purposes (including any actions taken after the date of the ROW Future Cash Payment that have a retroactive effect to the date of
      the ROW Future Cash Payment), without the prior written consent of Seller Parent.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(oo)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 5.08 of the Agreement is hereby amended by adding the following new clause immediately after clause (d) thereof:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;After the Closing, Buyer shall, and shall cause its Subsidiaries to, at the request of Seller Parent, provide reasonable cooperation to Seller Parent and its Subsidiaries relating to the Insulin
      Investigations and the Insulin Actions, including by (i) retaining and, upon request of Seller Parent, providing Seller Parent with any books, records and other data or information relating to any of the Insulin Investigations or the Insulin Actions
      and (ii) upon request of Seller Parent, making their respective employees, and using reasonable best efforts to make their respective consultants and independent contractors, reasonably available to assist with the Insulin Investigations</div>
    <div style="text-align: justify; margin-left: 108pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">11</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">and the Insulin Actions (including in connection with any investigation, prosecution, pretrial activities or trial relating to, or any compromise, settlement or other discharge of, any of the
      Insulin Investigations or the Insulin Actions). As used herein, &#8220;Insulin Investigations&#8221; shall have the meaning given in Item 10 of Section 9.02(b) of the Seller Parent Disclosure Letter.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(pp)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 5.13(a)(ii) of the Agreement is hereby amended by replacing the words &#8220;Equity Financing Letters&#8221; with the words &#8220;Amended Equity Financing Letters&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(qq)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 5.15 of the Agreement is hereby amended by adding the following sentence immediately after the last sentence thereof:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;Notwithstanding the foregoing, Seller Parent and Buyer acknowledge and agree that Buyer shall not be required to (a) replace a Credit Support Item or (b) indemnify and hold harmless Seller Parent
      and its Subsidiaries from and against any claims, losses, liabilities, damages, judgments, fines, penalties, costs and expenses, in each case, pursuant to this <u>Section 5.15</u> until after Seller Parent has identified such Credit Support Item to
      Buyer.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(rr)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The second sentence of Section 5.19 of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;Notwithstanding the immediately preceding sentence, if mutually agreed by Seller Parent and Buyer prior to the Closing, all or certain of the Seller Parent/Buyer Contracts may instead be assigned
      to Buyer or its Subsidiaries at the Closing or assigned to ROW Acquired Company or Irish Acquired Company prior to or at the Closing, rather than being terminated effective as of the Closing.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(ss)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 6.03(d) of the Agreement is hereby amended by replacing the words &#8220;Equity Financing Letter&#8221; with the words &#8220;Amended Equity Financing Letter&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(tt)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 8.05(b) of the Agreement is hereby amended by adding the following sentence immediately after the last sentence thereof:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;For the avoidance of doubt, Seller Parent shall have sole control over the Insulin Investigations and the Insulin Actions, with full authority over such matters (including full authority over the
      defense, prosecution and settlement or other resolution or disposition of the same), and Seller Parent shall be responsible for all expenses or costs incurred by Seller Parent and its Subsidiaries in connection with Seller Parent&#8217;s control over the
      Insulin Investigations and the Insulin Actions (including any such expenses or costs incurred by Seller Parent and its Subsidiaries in the defense, prosecution or settlement or other resolution or disposition of the same). Without limiting the
      foregoing, Seller Parent shall keep Buyer reasonably informed regarding any material developments in the Insulin Investigations.&#8221;</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">12</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #bfbfbf; background-color: #bfbfbf;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(uu)&#160;&#160; &#160; &#160;&#160; Section 8.07 of the Agreement is hereby amended by (i) replacing the words &#8220;adjustments of the Estimated Adjustment Amount&#8221; with the words &#8220;the Final Adjustment Amount&#8221; and (ii) replacing
      the words &#8220;Final Closing Cash Consideration&#8221; with &#8220;Final Adjustment Amount&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(vv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 8.10 of the Agreement is hereby amended by replacing the words &#8220;the Final Closing Cash Consideration&#8221; with the words &#8220;amounts paid under this Agreement for the ROW Acquired
      Company&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(ww)&#160;&#160;&#160;&#160;&#160;&#160; The Agreement is amended by replacing each reference to &#8220;Irish Estimated Closing Cash Consideration&#8221; with a reference to &#8220;Irish Closing Cash Consideration&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(xx)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Agreement is amended by replacing each reference to &#8220;TSA Management Committee&#8221; with a reference to &#8220;Transition Management Committee&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(yy)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Agreement is amended by replacing each reference to &#8220;Future Cash Consideration&#8221; with a reference to &#8220;Future Cash Payments&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(zz)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 9.02 of the Agreement is hereby amended by adding the following definitions in the appropriate alphabetical order therein:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Amendment Liabilities</u>&#8221; means all obligations and liabilities to the extent arising out of, relating to or otherwise in respect of (a) any of the amendments to Item 1 of the Business Steps
      Plan or to <u>Section 1.01</u>, <u>Section 1.02</u>, <u>Section 1.03</u>, <u>Section 1.04</u>, <u>Section 1.05(b)</u>, <u>Section 1.07</u> or <u>Section 9.02</u> to the extent the amendments to <u>Section 9.02</u> are related to the
      amendments to the aforementioned sections of <u>Article I</u>, (b) Item 4 of the Business Steps Plan and (c) any Taxes arising out of, relating to or otherwise in respect of the Business Steps Plan, in each case that would not have arisen absent the
      amendments to the Agreement effected by this Amendment; <u>provided</u>, <u>however</u>, that the Amendment Liabilities shall not include (i) any of the obligations and liabilities of Seller Parent and its Affiliates, or any of the advisors thereof
      (including Existing Counsel), in respect of evaluating, negotiating or documenting this Amendment, (ii) obligations and liabilities to the extent arising out of, relating to or otherwise in respect of Seller Parent or any of its Affiliates not
      performing their obligations under this Amendment or the Business Steps Plan or (iii) obligations and liabilities to the extent arising out of, relating to or otherwise in respect of the failure to achieve the Intended Tax Treatment.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>BPL</u>&#8221; means Biocon Pharma Limited, a company incorporated under the provisions of the Companies Act, 1956 and a wholly owned Subsidiary of Buyer Parent.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Estimated Adjustment Amount</u>&#8221; means (a) the Estimated Working Capital Adjustment Amount (which may be a negative number), <u>minus</u> (b) the </div>
    <div style="text-align: justify;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">13</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #bfbfbf; background-color: #bfbfbf;"></div>
    </div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">Estimated Assumed Indebtedness Amount, <u>plus</u> (c) the Estimated Closing Collaboration Adjustment Amount (which may be a negative number).</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Final Adjustment Amount</u>&#8221; means (a) the Working Capital Adjustment Amount (which may be a negative number) as finally determined pursuant to <u>Section 1.06</u>, <u>minus</u> (b) the
      Assumed Indebtedness Amount as finally determined pursuant to <u>Section 1.06</u>, <u>plus</u> (c) the Closing Collaboration Adjustment Amount (which may be a negative number) as finally determined pursuant to <u>Section 1.06</u>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Irish Closing Cash Consideration</u>&#8221; means $588,000,000 (five hundred eighty-eight million dollars).</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Irish Letter of Direction</u>&#8221; means the Funds Flow Letter of Instruction and Direction, dated on or about the Closing Date, by and among Buyer, Subsidiary Buyer, Irish Seller and the Irish
      Acquired Company.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>ROW Letter of Direction</u>&#8221; means the Funds Flow Letter of Instruction and Direction, dated on or about the Closing Date, by and among Buyer, Subsidiary Buyer, ROW Seller and the ROW Acquired
      Company.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>ROW Note&#8221;</u> means the promissory note, to be issued by ROW Acquired Company in favor of the ROW Seller pursuant to Item 4 of the Business Steps Plan, in substantially the form attached hereto
      as <u>Exhibit X</u>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Transition Management Committee</u>&#8221; has the meaning set forth in <u>Annex D</u>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(aaa)&#160;&#160;&#160;&#160;&#160;&#160; Section 9.02 of the Agreement is hereby amended by amending and restating the following definitions to have the following meanings:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Adjustment Amount</u>&#8221; means a number (which may be a negative number) equal to the Final Adjustment Amount.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Applicable Buyer</u>&#8221; means, with respect to any Acquired Equity Interests, the purchaser of such Acquired Equity Interests (which, for the avoidance of doubt, shall be (a) Buyer in the case of
      the Acquired ROW Equity Interests and (b) the Subsidiary Buyer in the case of the Irish New Equity Interests).</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Assumed Liabilities</u>&#8221; means all of Seller Parent&#8217;s and its Subsidiaries&#8217; obligations and liabilities to the extent arising out of, relating to or otherwise in respect of the Business, the
      Acquired Equity Interests or the Irish Redemption Equity Interests (in each case, including the ownership or operation thereof), whether any such obligation or liability arises before, at or after the Closing, is known or unknown or is contingent or
      accrued, including (a) the Amendment Liabilities and (b) all obligations and liabilities of Seller Parent or any of its Affiliates to the extent arising out of, relating to </div>
    <div style="text-align: justify; margin-left: 108pt;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">14</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #bfbfbf; background-color: #bfbfbf;"></div>
    </div>
    <div style="text-align: justify; margin-left: 108pt;"> <br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">or otherwise in respect of the ROW Note or any Assumed Indebtedness but excluding any obligation or liability set forth on Section 9.02(b) of the Seller Parent Disclosure Letter (the &#8220;<u>Business
        Retained Liabilities</u>&#8221;).</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Buyer Parent Equity Financing</u>&#8221; means the consummation of the Equity Transactions (as defined in the Buyer Parent Amended Equity Financing Letter) in accordance with the Buyer Parent Amended
      Equity Financing Letter, pursuant to which Buyer, Buyer Parent and BPL have agreed, on the terms and subject to the conditions set forth in the Buyer Parent Amended Equity Financing Letter, that (a) Buyer will issue (i) 145,011,221 newly issued
      shares of Buyer Common Stock to Buyer Parent in exchange for an approximately $500,000,000 (five hundred million dollars) payment from Buyer Parent to Buyer and (ii) 43,334,580 newly issued shares of Buyer Common Stock to BPL in exchange for an
      approximately $150,000,000 (one hundred fifty million dollars) payment from BPL to Buyer and (b) Buyer Parent and Buyer will convert the Buyer OCRPS into Buyer Common Stock, in the case of clause (a), immediately prior to the Closing.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Customer Contract</u>&#8221; means each Contract between Seller Parent or any of its Subsidiaries, on the one hand, and any customer of the Business (for the avoidance of doubt, including
      distributors) (in its capacity as such), on the other hand, to the extent relating to the Business.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Serum Equity Financing</u>&#8221; means the funding of the Equity Commitment (as defined in the Serum Amended Equity Financing Letter) in accordance with the Serum Amended Equity Financing Letter,
      pursuant to which Buyer and Serum have agreed, on the terms and subject to the conditions set forth in the Serum Amended Equity Financing Letter, that Buyer will issue 34,733,743 newly issued shares of Buyer Common Stock to Serum in exchange for a
      $150,000,000 (one hundred fifty million dollars) payment from Serum to Buyer, in each case, immediately prior to the Closing.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Subsidiary Buyer</u>&#8221; means Biocon Biologics UK Limited, a private limited company registered in England and Wales.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>VAT</u>&#8221; means (a) any tax imposed (i) in compliance with the Council Directive of 28 November 2006 on the common system of value added tax (EC Directive 2006/112), (ii) under the (Indian) Goods
      and Services Tax Act, 2017, or (iii) under the (UK) Value Added Tax Act 1994 or legislation or regulations supplemental thereto and (b) any other tax of a similar nature, however denominated, to the taxes referred to in clause (a) above, whether
      imposed in a member state of the European Union in substitution for, or levied in addition to, the taxes referred to in clause (a) above, or imposed elsewhere (including goods and services taxes, state or central value added taxes, indirect taxes and
      any cess, fee or surcharge thereon, but excluding Transfer Taxes).</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">15</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #bfbfbf; background-color: #bfbfbf;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Working Capital Target</u>&#8221; means $225,000,000 (two hundred twenty-five million dollars).</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(bbb)&#160;&#160;&#160;&#160;&#160; The definition of &#8220;Excluded Taxes&#8221; set forth in Section 9.02 of the Agreement is hereby amended by (i) amending and restating clause (d) in its entirety as follows &#8220;any Transfer Taxes or
      VAT for which Seller Parent is liable under <u>Section 5.06(b)</u> (it being understood that no Transfer Taxes or VAT shall be included in clause (a), (b) or (c) of this definition)&#8221; and (ii) adding the following proviso at the end of such
      definition &#8220;<u>provided</u> that &#8220;<u>Excluded Taxes</u>&#8221; shall not include any Taxes that are Amendment Liabilities&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(ccc)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The definition of &#8220;Fundamental Tax Matters&#8221; set forth in Section 9.02 of the Agreement is hereby amended by replacing the reference to &#8220;<u>Section 5.03(c)</u>&#8221; with a reference to &#8220;<u>Section


        5.03(b)</u>&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(ddd)&#160;&#160;&#160;&#160;&#160;&#160; The definition of &#8220;Irish Redemption Equity Interests&#8221; set forth in Section 9.02 of the Agreement is hereby amended by adding the parenthetical &#8220;(including any preference shares)&#8221;
      immediately after the words &#8220;equity interests&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(eee)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The definition of &#8220;Transaction Documents&#8221; set forth in Section 9.02 of the Agreement is hereby amended replacing the reference to &#8220;Equity Financing Letter&#8221; with a reference to &#8220;Amended
      Equity Financing Letters&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(fff)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The definition of &#8220;Transfer Taxes&#8221; set forth in Section 9.02 of the Agreement is hereby amended by adding the parenthetical &#8220;(other than VAT)&#8221; immediately after the word &#8220;Taxes&#8221; at the
      end of the sentence thereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(ggg) &#160;&#160;&#160;&#160;&#160; Section 9.02 of the Agreement is hereby amended by deleting the following definitions: &#8220;Closing Base Cash Consideration&#8221;, &#8220;Estimated Closing Cash Consideration&#8221;, &#8220;Final Closing Cash
      Consideration&#8221; and &#8220;TSA Management Committee&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(hhh)&#160;&#160;&#160;&#160;&#160;&#160; Section 9.03 of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;<u>Other Definition</u>. For purposes of this Agreement, the terms listed below have the meanings ascribed to them in the respective sections of this Agreement set forth below.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="1" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z6dd487dd25034353b97f91bc093af666">

        <tr>
          <td style="width: 71.16%; vertical-align: top;">
            <div style="font-weight: bold;">Term</div>
          </td>
          <td style="width: 28.84%; vertical-align: top;">
            <div style="font-weight: bold;">Location</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
            <div>Accessed Party</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
            <div>Section 4.03(a)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="1" cellpadding="1" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z69d676cfbfc747da81c0d670a52d2de0">

        <tr>
          <td style="width: 71.16%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div>Accessing Party</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 4.03(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Acquired Companies</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Acquisition</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.02(c)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Acquisition Engagement</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 9.16(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Agreement</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Preamble</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Amended Equity Financing Letters</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">16</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #bfbfbf; background-color: #bfbfbf;"></div>
    </div>
    <div><br>
    </div>
    <table cellspacing="1" cellpadding="1" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Announcement</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">5.05</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Anticipated Business Employees</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.27(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Assumed Indebtedness</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 5.13(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Benefits/Burdens Period</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.09(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Business Financial Information</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.10(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Business Financial Information Date</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.10(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Business Intellectual Property</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.14(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Business Interests</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Annex A</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Business Internal Reorganization</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">5.03</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Business Key Customers</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">2.17</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Business Key Suppliers</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">2.17</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Business Material Contracts</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.16(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Business Registered Intellectual Property</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.14(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Business Transfer Documents</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">5.21</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Preamble</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer Acquisition Engagement</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 9.17(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer Aggregate Cap</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 8.04(b)(ii)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer Basket Amount</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 8.04(b)(iv)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer Board</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer Counsel</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 9.17(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer De Minimis Amount</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 8.04(b)(iv)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer Debt Amount</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 6.03(f)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer General Cap</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 8.04(b)(ii)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer Indemnitees</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">8.02</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer Intellectual Property</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 3.12(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer Material Contracts</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 3.14(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer Parent Amended Equity Financing Letter</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer Parent Equity Financing Letter</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Buyer Parent Equity Financing Letter Amendment</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Claim</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 8.04(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Closing</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">1.01</font></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">17</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #bfbfbf; background-color: #bfbfbf;"></div>
    </div>
    <div><br>
    </div>
    <table cellspacing="1" cellpadding="1" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Closing Date</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">1.01</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Closing Statement</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.06(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Confidentiality Agreement</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 4.03(c)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Credit Support Items</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">5.15</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Debt Financing</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 5.13(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Debt Financing Agreements</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 9.19</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
            <div style="color: #000000;">Dedicated Business Employees</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
            <div>Section 4.03(d)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="1" cellpadding="1" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z78464d7e8eaa43628663593d04c46d81">

        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Delayed Transfer Company</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.09(d)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Direct Claim</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">8.06</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Disclosing Party</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 5.04(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>DPA</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">2.20</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Enforceability Exceptions</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.02(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Equity Financing Letters</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Estimated Assumed Indebtedness Amount</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.06(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Estimated Closing Collaboration Adjustment Amount</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.06(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Estimated Working Capital Adjustment Amount</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.06(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Exclusion Right</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.10(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Exclusion Right Exercise Date</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.10(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Exclusivity Period</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">5.01</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Existing Counsel</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 9.16(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>FCPA</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.19(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Financing</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 5.13(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Foreign Antitrust Approvals</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 5.02(a)(ii)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Foreign Antitrust Laws</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.07(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Future Cash Payments</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.05(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>HSR Act</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.07(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>HSR Approval</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 5.02(a)(i)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>ICC Rules</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 9.13(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Indemnified Party</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 8.04(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Indemnifying Party</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 8.04(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Independent Adjustment Expert</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.06(c)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Independent Valuation Expert</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 5.02(e)(i)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Information Security Reviews</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.14(l)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Intended Irish Tax Treatment</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 5.06(a)(iii)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Intended Tax Treatment</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 5.06(a)(iii)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">18</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #bfbfbf; background-color: #bfbfbf;"></div>
    </div>
    <div><br>
    </div>
    <table cellspacing="1" cellpadding="1" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Intended U.S. Tax Treatment</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 5.06(a)(iii)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Ireland Companies Act</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 3.11(f)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Irish Acquired Company</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Irish Acquisition</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.02(c)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Irish Future Cash Payment</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.05(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Irish Future Cash Payment Conditions</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.05(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Irish Redemption</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.02(c)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Irish Seller</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Irish Spin-Off</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Irish Subscription</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.02(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Labor Actions</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.27(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Law</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.07(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Legal Impediment</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.09(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Legal Impediment Delayed Asset/Liability</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.09(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Legal Impediment Delayed Assets/Liabilities</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.09(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
            <div>Legal Impediment Delayed Transfer</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
            <div>Section 1.09(b)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="1" cellpadding="1" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zfbe9a0c7e69c49da836a67b1ecff4a12">

        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Legal Impediment Delayed Transfer Date</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.09(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Licensed Business IP Contracts</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.14(c)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Licensed Buyer IP Contracts</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 3.12(c)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Liens</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.07(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Mylan Ireland</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Notice of Disagreement</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.06(c)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Order</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.07(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Other Approvals</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 5.02(a)(iii)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Outside Date</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 7.01(b)(i)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Parties</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Preamble</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Regulatory Approvals</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 5.02(a)(iii)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Requesting Party</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 5.04(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Required Payments</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 3.21(c)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Restraints</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 6.01(c)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Retained Names Materials</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">5.07</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Retained Records</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Annex A</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>ROW Acquired Company</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>ROW Acquisition</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.02(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>ROW Future Cash Payment</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.05(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>ROW Seller</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Seller Aggregate Cap</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 8.04(b)(i)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Seller Basket Amount</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 8.04(b)(iii)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Seller De Minimis Amount</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 8.04(b)(iii)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Seller General Cap</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 8.04(b)(i)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">19</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #bfbfbf; background-color: #bfbfbf;"></div>
    </div>
    <div><br>
    </div>
    <table cellspacing="1" cellpadding="1" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Seller Indemnitees</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">8.03</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Seller Parent</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Preamble</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Seller Parent Board</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Seller Privileges</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 9.16(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Sellers</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Serum Amended Equity Financing Letter</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Serum Equity Financing Letter</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Serum Equity Financing Letter Amendment</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>SHA Joinder</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Solvent</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 3.21(d)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Specified Assets</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.10(b)(i)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Specified Courts</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 9.12(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Specified Liabilities</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.10(b)(ii)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Specified Product</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.10(b)(iii)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Stock Rights</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.03(c)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Third Party Claim</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 8.05(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Transferred Business Records</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Annex A</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Transferred Contracts</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Annex A</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
            <div>Transferred IP</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
            <div>Annex A</div>
          </td>
        </tr>

    </table>
    <table cellspacing="1" cellpadding="1" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z4c1e3d2e7b7b4b70a1e956a61bb51b72">

        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Transferred IP Licenses</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Annex A</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Transferred Labeling and Marketing Materials</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Annex A</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Transferred Organizational Records</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Annex A</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Transition Period</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section <font style="font-weight: bold;">5.07</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>TSA Delayed Asset</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.09(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>TSA Delayed Transfer</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.09(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>TSA Delayed Transfer Date</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 1.09(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>UKBA</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.19(a)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Underlying Buyer Common Stock</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 3.03(b)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Voting Debt</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Section 2.03(c)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 71.16%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Written Consent</div>
          </td>
          <td style="width: 28.84%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div>Recitals&#8221;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 9.16 of the Agreement is hereby amended by adding the following words &#8220;and (iv) Slaughter and May&#8221; immediately after the words &#8220;Arthur Cox LLP&#8221; and replacing the word &#8220;and&#8221;
      immediately following the words &#8220;Saraf and Partners&#8221; with a comma.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(jjj)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 9.17 of the Agreement is hereby amended by adding the following words &#8220;and (iii) Matheson LLP&#8221; immediately after the words &#8220;Shardul Amarchand </div>
    <div style="text-align: justify;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">20</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #bfbfbf; background-color: #bfbfbf;"></div>
    </div>
    <div style="text-align: justify; margin-left: 72pt;"> <br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">Mangaldas &amp; Co&#8221; and replacing the word &#8220;and&#8221; immediately following the words Goodwin Procter (UK) LLP with a comma.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(kkk)&#160;&#160;&#160;&#160;&#160;&#160; Section 9.18 of the Agreement is hereby amended by replacing both parentheticals thereof with the following parenthetical &#8220;(including, at and following such time as they become
      Subsidiaries of Buyer, the Business Companies)&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(lll)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Agreement is hereby amended by adding the following Section 9.19 as a new section immediately after Section 9.18:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;SECTION 9.19.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Debt Financing Sources</u>. Notwithstanding anything in this Agreement to the contrary, each of the Parties on behalf of itself and each of their Affiliates hereby: (a)
      agrees that all Actions (whether in contract or in tort or otherwise) against the Debt Financing Sources arising out of or relating to this Agreement, the Debt Financing or the definitive agreements providing for the Debt Financing (collectively, the
      &#8220;<u>Debt Financing Agreements</u>&#8221;) or any of the transactions contemplated hereby or thereby or the performance of any services thereunder shall be governed by, and construed in accordance with, the laws of the State of New York, without giving
      effect to any choice of law or conflict of law rules or provisions (whether of the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York except as otherwise
      provided in any Debt Financing Agreement; (b) agrees that it will not bring or support any Action (whether in contract or in tort or otherwise) against the Debt Financing Sources arising out of or relating to this Agreement, the Debt Financing, the
      Debt Financing Agreements or any of the transactions contemplated hereby or thereby or the performance of any services thereunder in any forum other than (i) the Supreme Court of the State of New York, County of New York, or, if under applicable Law
      exclusive jurisdiction is vested in the federal courts, the United States District Court for the Southern District of New York (and the appellate courts thereof), or (ii) as otherwise provided in any Debt Financing Agreement; (c) agrees that service
      of process delivered in accordance with <u>Section 9.01</u> shall be effective service of process against it for any such Action brought in any such court; (d) agrees to waive and hereby waives, to the fullest extent permitted by applicable Law, any
      objection which it may now or hereafter have to the laying of venue of, and the defense of an inconvenient forum to the maintenance of, any such Action in any such court; (e) waives any right to the fullest extent permitted by applicable law to trial
      by jury with respect to any such Action; (f) agrees that none of the Debt Financing Sources will have any liability to any of Seller Parent and its Affiliates (including, prior to the Closing, the Business Companies) or their respective directors,
      officers, employees, agents, partners, managers, advisors, members and stockholders, and none of Seller Parent or its Affiliates (excluding, following the Closing, the Business Companies and any other obligor and security provider under the Debt </div>
    <div style="text-align: justify;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">21</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #bfbfbf; background-color: #bfbfbf;"></div>
    </div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">Financing Agreements) will have any liability to any of the Debt Financing Sources or their respective directors, officers, employees, agents, partners, managers, advisors, members and stockholders,
      in each case, relating to or arising out of this Agreement, the Debt Financing, the Debt Financing Agreements or any of the transactions contemplated hereby or thereby or the performance of any services thereunder, none of the Seller Parent and its
      Affiliates (including, prior to the Closing, the Business Companies) and their respective directors, officers, employees, agents, partners, managers, advisors, members and stockholders shall bring or support any Action (whether in contract or in tort
      or otherwise) against any of the Debt Financing Sources, and none of the Debt Financing Sources and their respective directors, officers, employees, agents, partners, managers, advisors, members and stockholders shall bring or support any Action
      (whether in contract or in tort or otherwise) against the Seller Parent or any of its Affiliates (excluding, following the Closing, the Business Companies and any other obligor and security provider under the Debt Financing Agreements), in each case,
      relating to or arising out of this Agreement, the Debt Financing, the Debt Financing Agreements or any of the transactions contemplated hereby or thereby or the performance of any services thereunder; and (g) agrees (x) that the Debt Financing
      Sources are express third party beneficiaries of, and may enforce, any of the provisions in this <u>Section 9.19</u> (or any of the defined terms used in this <u>Section 9.19</u>) and (y) to the extent any amendments to any provision of this <u>Section


        9.19</u> (or any of the defined terms used in this <u>Section 9.19</u> or any other provision of this Agreement to the extent a modification, waiver or termination of such defined term or provision would modify the substance of this <u>Section
        9.19</u> or such defined terms) are adverse to the Debt Financing Sources, such provisions shall not be amended without the prior written consent of the Debt Financing Sources.&#160; Notwithstanding anything contained herein to the contrary, nothing in
      this <u>Section 9.19</u> shall in any way affect a party&#8217;s rights and remedies against the Debt Financing Sources or Buyer or its Affiliates under the Debt Financing Agreements to the extent they are a party thereto.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(mmm)&#160;&#160;&#160;&#160; Clause (xi) on Annex B of the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;(xi) <u>Closing Working Capital</u>.&#160; In the event that the Closing Working Capital is a positive amount, current assets included in the Closing Working Capital up to a maximum amount equal to the
      lesser of (A) Closing Working Capital and (B) the Working Capital Target.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(nnn)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Annex B of the Agreement is hereby amended by adding the following as a new clause (xiii) immediately after clause (xii) thereof:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">&#8220;(xiii) <u>Insulin Actions</u>. All Actions, claims and settlements (in each case, whether or not brought, asserted, in existence or pending, and including any </div>
    <div style="text-align: justify;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">22</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #bfbfbf; background-color: #bfbfbf;"></div>
    </div>
    <div style="text-align: justify; margin-left: 108pt;"> <br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">payment or rights accruing from such Actions, claims and settlements) that may be brought or asserted by Seller Parent, any of its Subsidiaries or the Business relating to the Commercialization,
      development or manufacturing of insulin glargine Products (collectively, the &#8220;Insulin Actions&#8221;), in each case, to the extent arising out of or relating to Seller Parent&#8217;s operation of the Business prior to the Closing.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(ooo)&#160; &#160; &#160;&#160; Part A of <u>Annex C</u> of the Agreement is hereby amended and restated in its entirety to be in the form of <u>Exhibit A</u> hereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(ppp)&#160; &#160;&#160;&#160;&#160; Part B of <u>Annex C</u> of the Agreement is hereby amended by replacing the word &#8220;procuring&#8221; with the words &#8220;to procure&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(qqq) &#160; &#160;&#160;&#160; <u>Annex D</u> of the Agreement is hereby amended and restated in its entirety to be in the form of <u>Exhibit B</u> hereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(rrr)&#160;&#160; &#160; &#160;&#160;&#160; The Agreement is hereby amended by adding <u>Exhibit I-C</u> and <u>Exhibit I-D</u> as new exhibits to the Agreement in the form of <u>Exhibit C-1</u> and <u>Exhibit C-2</u> hereto,
      respectively.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(sss)&#160; &#160; &#160;&#160;&#160;&#160; <u>Exhibit III</u> is hereby amended and restated in its entirety to read &#8220;[RESERVED]&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(ttt)&#160;&#160; &#160;&#160; &#160;&#160;&#160; <u>Exhibit V</u> of the Agreement is hereby amended and restated in its entirety to be in the form of <u>Exhibit D</u> hereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(uuu)&#160; &#160; &#160;&#160; <u>Exhibit VI</u> of the Agreement is hereby amended and restated in its entirety to be in the form of <u>Exhibit E</u> hereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(vvv)&#160;&#160;&#160; &#160;&#160; <u>Exhibit VII</u> of the Agreement is hereby amended and restated in its entirety to be in the form of <u>Exhibit F</u> hereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(www)&#160; &#160;&#160; <u>Exhibit VIII</u> of the Agreement is hereby amended and restated in its entirety to be in the form of <u>Exhibit G</u> hereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(xxx)&#160;&#160;&#160; &#160;&#160; The Agreement is hereby amended by adding <u>Exhibit X</u> as a new exhibit to the Agreement in the form of <u>Exhibit H</u> hereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Effect of Amendment</u>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each Party acknowledges and agrees that this Amendment constitutes an instrument in writing on behalf of each of the Parties in accordance with Section 9.05 of the Agreement. For the
      avoidance of doubt, references to the date of the Agreement, and references to the &#8220;date hereof&#8221;, &#8220;the date of this Agreement&#8221; or words of similar meaning in the Agreement shall continue to refer to February 27, 2022.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">23</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #bfbfbf; background-color: #bfbfbf;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(b)&#160;&#160; &#160; &#160;&#160;&#160;&#160; Notwithstanding anything to the contrary in the Agreement: (i) Seller Parent and its Affiliates shall in no event be in breach of any covenant or agreement contained in the Agreement or
      any other Transaction Document, and the representations and warranties of Seller Parent and its Affiliates contained in the Agreement and the other Transaction Documents shall in no event be determined to be inaccurate, in each case, to the extent
      resulting from any of the amendments to the Agreement effected by this Amendment (other than, for the avoidance of doubt, (A) to the extent Seller Parent or any of its Affiliates do not perform their respective obligations under this Amendment and
      (B) to the extent changes are expressly made by this Amendment to provisions in the Transaction Documents (for example, the change to the Working Capital Target)); (ii) in no event shall the ROW Note be included in the Working Capital Adjustment
      Amount, the Assumed Indebtedness Amount, the Closing Collaboration Adjustment Amount or the Buyer Debt Amount (in each case, including any estimate thereof), or otherwise constitute Indebtedness of Seller Parent, Buyer or any of their respective
      Affiliates for purposes of the Agreement; (iii) in no event shall the ROW Note (or any accounts, balances, payables, receivables or Indebtedness thereunder) be considered Intercompany Accounts or Business Intercompany Contracts for purposes of the
      Agreement; (iv) in no event shall the equity interests in the ROW Acquired Company issued pursuant to the Buyer ROW Contribution be considered ROW Acquired Equity Interests for purposes of the Agreement; (v) Buyer and its Affiliates shall in no event
      be in breach of any covenant or agreement contained in the Agreement or any other Transaction Document, and the representations and warranties of Buyer and its Affiliates contained in the Agreement and the other Transaction Documents shall in no
      event be determined to be inaccurate, in each case, to the extent resulting from any of the amendments to the Agreement effected by this Amendment (other than, for the avoidance of doubt, to the extent Buyer or any of its Affiliates do not perform
      their respective obligations under this Amendment); and (vi) this Amendment constitutes (A) the consent of Seller Parent under the Transaction Documents to the Buyer Parent Equity Financing Letter Amendment and the Serum Equity Financing Letter
      Amendment and (B) the mutual agreement of the Parties that the Buyer Parent Equity Financing Letter Amendment and the Serum Equity Financing Letter Amendment will not prevent or impede the Intended Tax Treatment.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Limited Amendment</u>.&#160; Except as expressly set forth in paragraphs 1 and 2 above, this Amendment shall not be deemed to amend, waive, affect or otherwise alter any term or provision
      of the Agreement or the other Transaction Documents, and all terms and provisions of the Agreement and the other Transaction Documents shall continue in full force and effect.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Miscellaneous</u>.&#160; The provisions set forth in Sections 9.01 and 9.04 through 9.18 of the Agreement (as amended by this Amendment) shall apply to this Amendment, <font style="font-style: italic;">mutatis mutandis</font>, and are incorporated by reference as if fully set forth herein.</div>
    <div><br>
    </div>
    <div style="text-align: center;">[<font style="font-style: italic;">Remainder of page intentionally left blank</font>]</div>
    <div style="text-align: center;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">24</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;">IN WITNESS WHEREOF, the Parties have duly executed this Amendment, all as of the date first written above.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; border-collapse: separate; font-family: 'Times New Roman'; font-size: 10pt;">

          <tr>
            <td valign="top" style="width: 50%;">&#160;</td>
            <td valign="top" rowspan="1" colspan="4"><strong></strong>VIATRIS INC.</td>
          </tr>
          <tr>
            <td valign="top" style="width: 50%;">&#160;</td>
            <td valign="top" style="width: 3%;">&#160;</td>
            <td valign="top" colspan="1" style="width: 1%;">&#160;</td>
            <td valign="top" colspan="2">&#160;</td>
            <td valign="top" style="width: 11%;">&#160;</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="width: 50%; padding-bottom: 2px;">
              <div align="left" style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt"><br>
              </div>
            </td>
            <td valign="top" style="width: 3%; padding-bottom: 2px;">
              <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: right;">by</div>
            </td>
            <td valign="top" colspan="1" style="width: 1%; padding-bottom: 2px;">&#160;</td>
            <td align="left" valign="top" nowrap="nowrap" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0);">/s/ Anil Amin</td>
            <td valign="top" style="width: 11%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="top" style="width: 50%;">&#160;</td>
            <td valign="top" style="width: 3%;">&#160;</td>
            <td valign="top" colspan="1" style="width: 1%;">&#160;</td>
            <td align="left" valign="bottom" nowrap="nowrap" style="width: 4%;">Name:</td>
            <td align="left" valign="bottom" nowrap="nowrap" style="width: 31%;">Anil Amin <br>
            </td>
            <td valign="top" style="width: 11%;">&#160;</td>
          </tr>
          <tr>
            <td valign="top" rowspan="1" style="width: 50%;">&#160;</td>
            <td valign="top" rowspan="1" style="width: 3%;">&#160;</td>
            <td valign="top" rowspan="1" colspan="1" style="width: 1%;">&#160;</td>
            <td align="left" valign="bottom" nowrap="nowrap" rowspan="1" style="width: 4%;">Title: <br>
            </td>
            <td align="left" valign="bottom" nowrap="nowrap" rowspan="1" style="width: 31%;">Authorized Signatory <br>
            </td>
            <td valign="top" rowspan="1" style="width: 11%;">&#160;</td>
          </tr>
          <tr>
            <td valign="top" style="width: 50%;">&#160;</td>
            <td valign="top" style="width: 3%;">&#160;</td>
            <td valign="top" colspan="1" style="width: 1%;">&#160;</td>
            <td valign="top" colspan="2">&#160;</td>
            <td valign="top" style="width: 11%;">&#160;</td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">IN WITNESS WHEREOF, the Parties have duly executed this Amendment, all as of the date first written above.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; border-collapse: separate; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" rowspan="1" colspan="4">BIOCON BIOLOGICS LIMITED</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" style="width: 3%;">&#160;</td>
              <td valign="top" colspan="1" style="width: 1%;">&#160;</td>
              <td valign="top" colspan="2">&#160;</td>
              <td valign="top" style="width: 11%;">&#160;</td>
            </tr>
            <tr>
              <td align="left" valign="top" style="width: 50%; padding-bottom: 2px;">
                <div align="left" style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt"><br>
                </div>
              </td>
              <td valign="top" style="width: 3%; padding-bottom: 2px;">
                <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: right;">by</div>
              </td>
              <td valign="top" colspan="1" style="width: 1%; padding-bottom: 2px;">&#160;</td>
              <td align="left" valign="top" nowrap="nowrap" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0);">/s/ Chinappa M.B.</td>
              <td valign="top" style="width: 11%; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" style="width: 3%;">&#160;</td>
              <td valign="top" colspan="1" style="width: 1%;">&#160;</td>
              <td align="left" valign="bottom" nowrap="nowrap" style="width: 4%;">Name:</td>
              <td align="left" valign="bottom" nowrap="nowrap" style="width: 31%;">Chinappa M.B. <br>
              </td>
              <td valign="top" style="width: 11%;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" style="width: 50%;">&#160;</td>
              <td valign="top" rowspan="1" style="width: 3%;">&#160;</td>
              <td valign="top" rowspan="1" colspan="1" style="width: 1%;">&#160;</td>
              <td align="left" valign="bottom" nowrap="nowrap" rowspan="1" style="width: 4%;">Title: <br>
              </td>
              <td align="left" valign="bottom" nowrap="nowrap" rowspan="1" style="width: 31%;">Chief Financial Officer <br>
              </td>
              <td valign="top" rowspan="1" style="width: 11%;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" style="width: 3%;">&#160;</td>
              <td valign="top" colspan="1" style="width: 1%;">&#160;</td>
              <td valign="top" colspan="2">&#160;</td>
              <td valign="top" style="width: 11%;">&#160;</td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
    </div>
    <br>
  </div>
  <div><br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Cravath, Swaine & Moore LLP
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: Arial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
  <div style="font-family: 'Times New Roman'; text-align: right; font-weight: bold;">Exhibit 99.1<br>
  </div>
  <div> <br>
  </div>
  <div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: Arial; font-size: 10pt; font-weight: bold;">Viatris Completes Biosimilars Transaction with Biocon Biologics</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: Arial; font-size: 10pt; font-style: italic;">Receives a $2 Billion&#160;Cash Payment and&#160;$1 Billion&#160;of Convertible Preferred Equity Representing a Stake of at Least 12.9% (on a Fully Diluted Basis) in Biocon
      Biologics</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: Arial; font-size: 10pt; font-style: italic;">Marks the First in a Series of Expected Initiatives to Reshape and Rebase Viatris, Aimed at Setting it Up for Long-term Growth</div>
    <div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: Arial; font-size: 10pt;"><font style="font-size: 10pt; font-family: Arial; font-weight: bold;">PITTSBURGH, Nov. 29, 2022</font> &#8211; <font style="font-size: 10pt; font-family: Arial; color: rgb(0, 0, 255);"><u>Viatris
            Inc.</u></font> (NASDAQ: VTRS)&#160;today announced that it has closed its transaction with Biocon Biologics Limited (&#8220;Biocon Biologics&#8221;), creating what Viatris expects to be a unique fully vertically integrated global biosimilars leader. Viatris
        and Biocon Biologics have entered a Transition Services Agreement (TSA) pursuant to which Viatris will provide commercialization and certain other transition services for an expected two-year period intended to ensure business continuity for
        patients, customers and colleagues. Upon the completion of the transition services, Biocon Biologics will assume responsibility of commercial, regulatory and other related services.</div>
      <div><br>
      </div>
    </div>
    <div style="text-align: left; font-family: Arial; font-size: 10pt;">Viatris Executive Chairman&#160;<font style="font-size: 10pt; font-family: Arial; font-weight: bold; color: rgb(0, 0, 255);"><u>Robert J. Coury</u></font>&#160;said:&#160;&#8220;Today is a very exciting
      day in the continued evolution of Viatris. The closing today of the Biocon Biologics transaction represents the completion of the first in a series of achievements against the number of initiatives we laid out recently in our strategic update on Nov.
      7 as part of our well-defined plan for Viatris. While we will continue to further execute against this plan, we also look forward as now a significant shareholder of Biocon Biologics to supporting Kiran Mazumdar-Shaw, Executive Chairperson of Biocon
      Limited and Biocon Biologics, and her team to optimize the value of Biocon Biologics.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: Arial; font-size: 10pt;">Viatris President&#160;<font style="font-size: 10pt; font-family: Arial; font-weight: bold; color: rgb(0, 0, 255);"><u>Rajiv Malik</u></font><font style="font-size: 10pt; font-family: Arial; color: rgb(0, 0, 255);">&#160;</font>said: &#8220;The closing of our biosimilars transaction with<font style="font-size: 10pt; font-family: Arial; color: rgb(0, 0, 0);"> Biocon Biologics marks the next natural step in the evolution of our collaboration
        together. We are deeply committed to doing our part in helping Biocon Biologics succeed in the creation of what we believe will be a true global, vertically integrated biosimilars leader. As we look to Viatris&#8217; future, we are also excited to focus
        our energy, resources and efforts on executing our own strategy of moving up the value chain and providing access to more complex and novel products.&#8221;</font></div>
    <div><br>
    </div>
    <div>
      <div style="text-align: left; font-family: Arial; font-size: 10pt;">Under the terms of the transaction agreement, Viatris received $3 billion&#160;in consideration in the form of a&#160;$2 billion&#160;cash payment and&#160;$1 billion&#160;of convertible preferred equity
        representing a stake of at least 12.9 % (on a fully diluted basis) in Biocon Biologics. Viatris also is entitled to&#160;$335 million&#160;of additional cash payments in 2024.</div>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: Arial; font-size: 10pt; font-weight: bold;">Financial Impact of Completion of the Biosimilars Transaction</div>
      <div style="text-align: left; font-family: Arial; font-size: 10pt;">As previously stated, the Company&#8217;s financial guidance ranges for total revenues, adjusted EBITDA and free cash flows for the year ending December 31, 2022, do not include the impact
        of the closing of the transaction with Biocon Biologics.&#160; The Company expects its reported results for the year ending December 31, 2022, to be impacted by the closing of the transaction as follows:</div>
      <div><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z1a85dcb88df045df97097a7a3567e1bd" class="DSPFListTable" style="font-family: Arial; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: Arial; font-size: 10pt;"><font style="font-family: Times New Roman">&#9679;</font></td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: Arial; font-size: 10pt;">The Company expects its reported total revenues and adjusted EBITDA for the year to be lower by approximately $80 million and $20 million, respectively.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zb7ff4fa6bf8b4b1fa96496a10bfc65ca" class="DSPFListTable" style="font-family: Arial; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: Arial; font-size: 10pt;">&#9679;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: Arial; font-size: 10pt;">The Company expects to report the $2 billion of cash proceeds, offset by the impact of certain deal related adjustments, as cash flows from investing activities. Additionally, the Company
                expects to incur approximately $400 million of certain deal related expenses, primarily taxes and associated transactions costs. As a result, the Company expects these deal related expenses to lead to lower reported cash flows from
                operating activities, and consequently free cash flow, for the year.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: Arial; font-size: 10pt; font-weight: bold;">Capital Allocation</div>
    </div>
    <div style="text-align: left; font-family: Arial; font-size: 10pt;">The Company expects to use the net divestiture cash from the biosimilars transaction to:</div>
    <table cellspacing="0" cellpadding="0" id="ze708ec6c4ff84577b4b39be4fdeac086" class="DSPFListTable" style="font-family: Arial; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 20.5pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: Arial; font-size: 10pt;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: Arial; font-size: 10pt;">Pay down additional short-term debt and accelerate its progress towards $6.5 billion of Phase 1 debt reduction</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z2a47290e6a1d40fcaa4dec0c4c318507" class="DSPFListTable" style="font-family: Arial; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 20.5pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: Arial; font-size: 10pt;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: Arial; font-size: 10pt;">And, in combination with cash on hand, to:</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z52930e1f9e2f4ebab4adc138a38cd82c" class="DSPFListTable" style="font-family: Arial; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 56.5pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: Arial; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: Arial; font-size: 10pt;">Fund the previously announced ophthalmology acquisitions totaling approximately $700 to $750 million, anticipated to close in the first quarter of 2023, and</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z08f311635bc448d087bd00fc79678ab2" class="DSPFListTable" style="font-family: Arial; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 56.5pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: Arial; font-size: 10pt;">o</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: Arial; font-size: 10pt;">Begin to execute on the previously announced share buyback authorization in 2023.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: left; font-family: Arial; font-size: 10pt; font-weight: bold;">About Viatris</div>
    <div style="text-align: left; font-family: Arial; font-size: 10pt;"><font style="color: rgb(0, 0, 255); font-family: Arial; font-size: 10pt;"><u>Viatris</u><u>
          Inc.</u></font><font style="font-size: 10pt; font-family: Arial;"> (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations,
        develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>. Formed in November 2020, Viatris brings together scientific,
        manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris&#8217; portfolio comprises more than 1,400 approved
        molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With
        approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at </font><font style="color: rgb(0, 0, 255); font-family: Arial; font-size: 10pt;"><u>viatris.com</u></font><font style="font-size: 10pt; font-family: Arial;"> and </font><font style="color: rgb(0, 0, 255); font-family: Arial; font-size: 10pt;"><u>investor.viatris.com</u></font><font style="font-size: 10pt; font-family: Arial;">, and connect with
        us on Twitter at </font><font style="color: rgb(0, 0, 255); font-family: Arial; font-size: 10pt;"><u>@ViatrisInc</u></font><font style="font-size: 10pt; font-family: Arial;">, </font><font style="color: rgb(0, 0, 255); font-family: Arial; font-size: 10pt;"><u>LinkedIn</u></font><font style="font-size: 10pt; font-family: Arial;"> and </font><font style="color: rgb(0, 0, 255); font-family: Arial; font-size: 10pt;"><u>YouTube</u></font><font style="font-size: 10pt; font-family: Arial;">.</font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: Arial; font-size: 10pt; font-weight: bold;">Forward-looking Statements</div>
    <div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: Arial; font-size: 10pt;">This press release includes statements that constitute &#8220;forward-looking statements.&#8221; These statements are made pursuant to the safe harbor provisions of the Private Securities
        Litigation Reform Act of 1995. Such forward looking statements may include statements about transition services agreements; the closing today of the Biocon Biologics transaction represents the completion of the first in a series of achievements
        against the number of initiatives we laid out recently in our strategic update on Nov. 7 as part of our well-defined plan for Viatris; while we will continue to further execute against this plan, we also look forward as now a significant
        shareholder of Biocon Biologics to supporting Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited and Biocon Biologics, and her team to optimize the value of Biocon Biologics; <font style="font-size: 10pt; font-family: Arial; color: rgb(0, 0, 0);">we are deeply committed to doing our part in helping Biocon Biologics succeed in the creation of what we believe will be a true global, vertically integrated biosimilars leader; as we look to Viatris&#8217; future, we are also excited to
          focus our energy, resources and efforts on executing our own strategy of moving up the value chain and providing access to more complex and novel products; </font>under the terms of the transaction agreement, Viatris received $3 billion&#160;in
        consideration in the form of a&#160;$2 billion&#160;cash payment and&#160;$1 billion&#160;of convertible preferred equity representing a stake of at least 12.9 % (on a fully diluted basis) in Biocon Biologics;<font style="font-size: 10pt; font-family: Arial; color: rgb(0, 0, 0);">&#160;</font>Viatris is entitled to&#160;$335 million&#160;of additional cash payments in 2024; financial impact of completion of the Biosimilars Transaction; as previously stated, the Company&#8217;s financial guidance ranges for total revenues,
        adjusted EBITDA and free cash flows for the year ending December 31, 2022, do not include the impact of the closing of the transaction with Biocon Biologics; the Company expects its reported results for the year ending December 31, 2022, to be
        impacted by closing of the transaction as follows: the Company expects its reported total revenues and adjusted EBITDA for the year to be lower by approximately $80 million and $20 million, respectively and the Company expects to report the $2
        billion of cash proceeds, offset by the impact of certain deal related adjustments, as cash flows from investing activities; the Company expects to incur approximately $400 million of certain deal related expenses, primarily taxes and associated
        transactions costs; as a result, the Company expects these deal related expenses to lead to lower reported cash flows from operating activities, and consequently free cash flow, for the year; expects to use the net divestiture cash from the
        biosimilars transaction to: pay down additional short-term debt and accelerate its progress towards $6.5 billion of Phase 1 debt reduction, and, in combination with cash on hand, to fund the previously announced ophthalmology acquisitions totaling
        approximately $700 to $750 million, anticipated to close in the first quarter of 2023, and begin to execute on the previously announced share buyback authorization in 2023. Factors that could cause or contribute to such differences include, but are
        not limited to: the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by the COVID-19 pandemic; that the transaction between Viatris and Biocon Biologics Limited, pursuant
        to which Viatris contributed its biosimilar products and programs to Biocon Biologics in exchange for cash consideration and a convertible preferred equity interest in Biocon Biologics (the &#8220;Biocon Biologics Transaction&#8221;) and other strategic
        initiatives, including potential divestitures, may not achieve their intended benefits; the integration of Mylan N.V. and Pfizer Inc.&#8217;s Upjohn business (the &#8220;Upjohn Business&#8221;), which combined to form Viatris (the &#8220;Combination&#8221;) and the
        implementation of our global restructuring initiatives being more difficult, time consuming or costly than expected, or being unsuccessful; the ability to achieve expected benefits, synergies, and operating efficiencies in connection with the
        Combination or its restructuring initiatives within the expected timeframe or at all; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any
        regulatory, legal or other impediments to Viatris&#8217; ability to bring new products to market, including but not limited to &#8220;at-risk&#8221; launches; Viatris&#8217; or its partners&#8217; ability to develop, manufacture, and commercialize products; the scope, timing
        and outcome of any ongoing legal proceedings, and the impact of any such proceedings; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations; the
        ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris&#8217; or its partners&#8217; customer and supplier relationships and customer purchasing patterns;
        the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management; and the other risks described in Viatris&#8217; filings with the Securities and Exchange
        Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC&#8217;s Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to
        update these statements for revisions or changes after the date of this release other than as required by law.</div>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #BFBFBF; background-color: #BFBFBF; clear: both;"></div>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: Arial; font-size: 10pt; font-weight: bold;">Non-GAAP Financial Measures</div>
    <div><br>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: Arial; font-size: 10pt;">This press release includes the presentation and discussion of certain financial information that differs from what is reported under accounting principles
        generally accepted in the United States (&#8220;U.S. GAAP&#8221;). These&#160;non-GAAP&#160;financial measures, including adjusted EBITDA and free cash flow, are presented in order to supplement investors&#8217; and other readers&#8217; understanding and assessment of the financial
        performance of Viatris. Free cash flow refers to U.S. GAAP net cash provided by operating activities, less capital expenditures. For the third quarter of 2022, Viatris calculated adjusted EBITDA as U.S. GAAP net earnings (loss) adjusted for income
        tax provision (benefit), interest expense and depreciation and amortization (to get to EBITDA) and further adjusted for share-based compensation expense, litigation settlements and other contingencies, net and restructuring, acquisition related and
        other special items.</div>
    <div><br>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: Arial; font-size: 10pt;">Viatris has provided reconciliations of historical&#160;non-GAAP&#160;financial measures to the most directly comparable U.S. GAAP financial measures. Investors and
        other readers are encouraged to review the related U.S. GAAP financial measures and the reconciliations of the&#160;non-GAAP&#160;measures to their most directly comparable U.S. GAAP measures set forth in this release on our website
        at&#160;https://investor.viatris.com/financial-information/non-gaap-reconciliations,&#160;and investors and other readers should consider&#160;non-GAAP&#160;measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial
        performance prepared in accordance with U.S. GAAP.</div>
    <div><br>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: Arial; font-size: 10pt;">With regard to the completion of the biosimilars transaction, Viatris is not providing forward-looking disclosures for the expected impact on the most directly
      comparable U.S. GAAP measure, net earnings (loss), or a quantitative reconciliation of the expected impact on adjusted EBITDA to a projected impact on U.S. GAAP net earnings (loss) because it is unable to predict with reasonable certainty the
      ultimate outcome of certain significant items, including integration and acquisition-related expenses, restructuring expenses, asset impairments, litigation settlements and other contingencies, such as changes to contingent consideration and certain
      other gains or losses, as well as related income tax accounting, because certain of these items have not occurred, are out of the Company&#8217;s control and/or cannot be reasonably predicted without unreasonable effort. These items are uncertain, depend
      on various factors, and could have a material impact on U.S. GAAP reported results for the period.</div>
    <div><br>
    </div>
    <div>
      <div style="text-align: left; font-family: Arial; font-size: 10pt; font-weight: bold;">Contacts:</div>
      <div style="text-align: left; font-family: Arial; font-size: 10pt;">Media:</div>
      <div style="text-align: left; font-family: Arial; font-size: 10pt;">+1.724.514.1968</div>
      <div style="text-align: left; color: rgb(0, 0, 255); font-family: Arial; font-size: 10pt;"><u>Communications@viatris.com</u></div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: Arial; font-size: 10pt;">Jennifer Mauer</div>
      <div style="text-align: left; color: rgb(0, 0, 255); font-family: Arial; font-size: 10pt;"><u>Jennifer.Mauer@viatris.com</u></div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: Arial; font-size: 10pt;">Matt Klein</div>
      <div style="text-align: left; color: rgb(0, 0, 255); font-family: Arial; font-size: 10pt;"><u>Matthew.Klein@viatris.com</u></div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: Arial; font-size: 10pt;">Investors:</div>
      <div style="text-align: left; font-family: Arial; font-size: 10pt;">+1.724.514.1813</div>
      <div style="text-align: left; color: rgb(0, 0, 255); font-family: Arial; font-size: 10pt;"><u>InvestorRelations@viatris.com</u></div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: Arial; font-size: 10pt;">Bill Szablewski</div>
      <div style="text-align: left; color: rgb(0, 0, 255); font-family: Arial; font-size: 10pt;"><u>William.Szablewski@viatris.com</u></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>vtrs-20221128.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://viatris.com/20221128" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:vtrs="http://viatris.com/20221128" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="vtrs-20221128_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="vtrs-20221128_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://viatris.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>vtrs-20221128_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>vtrs-20221128_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://viatris.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="vtrs-20221128.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://viatris.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139954081072992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 28,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Viatris Inc<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-4364296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1000 Mylan Boulevard<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Canonsburg<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">15317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">514-1800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001792044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VTRS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vtrs-20221128.xsd" xlink:type="simple"/>
    <context id="c20221128to20221128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001792044</identifier>
        </entity>
        <period>
            <startDate>2022-11-28</startDate>
            <endDate>2022-11-28</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20221128to20221128"
      id="Fact_e5d797da3d57472ba710ea0d5b8747c4">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20221128to20221128"
      id="Fact_68740d7e391e48c88f29d1ccc03be8c7">0001792044</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20221128to20221128"
      id="Fact_6e1c3a5d83c24a4fba3e23f8cf8407b6">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20221128to20221128"
      id="Fact_3a032140668947acbcd9f3092fe10e5d">2022-11-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20221128to20221128"
      id="Fact_b58e9d79181d436c81c47605852b3cb6">Viatris Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20221128to20221128"
      id="Fact_085cc3bf6e7c4115b4f7f88d510664cd">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20221128to20221128"
      id="Fact_013104b11bbe4c22b5be685dbb6c6e84">001-39695</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20221128to20221128"
      id="Fact_6e2ce73ca0c84a5db4f78eb363b265c9">83-4364296</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20221128to20221128"
      id="Fact_72b50815798848f58c7d97cf397f8480">1000 Mylan Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20221128to20221128"
      id="Fact_f9329242c5cf42b88f942f207f89ae20">Canonsburg</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20221128to20221128"
      id="Fact_031e1e52ec634a0c8a23b1179a1a5644">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20221128to20221128"
      id="Fact_37f62a3a82484ab8aae7871945ee2317">15317</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20221128to20221128"
      id="Fact_30e620a1e64d4822b525a13f6654b064">724</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20221128to20221128"
      id="Fact_cdaa16584b8f4eea95f716bdd230c982">514-1800</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20221128to20221128"
      id="Fact_6c3105f683394a4d98b5a86d5ec7fc41">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20221128to20221128"
      id="Fact_abaa83f172c340deb4d5e9cba6d41bb0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20221128to20221128"
      id="Fact_14858c59b469400d9fb3ee99d3eaf108">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20221128to20221128"
      id="Fact_cc296257a6ba405992e7289f3aa40b4a">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20221128to20221128"
      id="Fact_e5cc3d5e7f2d42aba75eb3aca7a8487f">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20221128to20221128"
      id="Fact_b2417f93aefb45baa106a0acf3a57dee">VTRS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20221128to20221128"
      id="Fact_bb49caa5b7964fef9244ba5a01bcd9a4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20221128to20221128"
      id="Fact_4c1970b874a84c1a86695eaf76bfb80a">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M25T'^'VEE/UHN$-L\3^(T3]02P,$%     @ M4-]59^@&_"Q @  X@P   T
M  !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV
M!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-S
MS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.
MIM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#
M%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6
M#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#H
MG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_
MC!9B7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK
M'O;^RPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?
MK7/--;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*
MLN3ZQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-
MM[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]
MK-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7
MCX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L
M"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9G
MD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ M4-]59>*
MNQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q
M%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(
MMB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!
M;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B
M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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MOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ M4-]50=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "U
M0WU51C!8&.X    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " "U0WU5F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +5#?55_VY&H
M200  (\0   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " "U0WU5GZ ;\+$"  #B#   #0
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:+GAM;%!+!08     "0 ) #X"  #L$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://viatris.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex2-1.htm</File>
    <File>ex99-1.htm</File>
    <File>vtrs-20221128.xsd</File>
    <File>vtrs-20221128_lab.xml</File>
    <File>vtrs-20221128_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vtrs-20221128_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vtrs-20221128_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vtrs-20221128.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "vtrs",
   "nsuri": "http://viatris.com/20221128",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "c20221128to20221128",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://viatris.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "c20221128to20221128",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://viatris.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950157-22-001253-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950157-22-001253-xbrl.zip
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M@-2-<2%*Q;F9RBR)?<X#DY.SD"CL+A1H"HL^QD2A4JO-BH@M-K1OF AI@\=
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M-O62Y5UP;NDZQB/I\V(2WS \3A5E4C5#ERT%[W:GK P8<VHHGO:4F"SG(0D
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MJ2ZJQ<1OH%2G>O4X=8%MKZ)Y%5*8RNO(UJ84OFI7,K?8L&%FW@=^6QEJ:])
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M^O5Q2,O(Y@^++#!3,2-7@XDN/]=MS=J&/L.]X7$G8RO,J,D=:QL^J$93'3[
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MKCF/ZLLO?QK%P9P^3+)I"!_^/U!+ P04    " "U0WU5+T@+R,,7  "P8P
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M6SJP1:[4$CZK=82/R#QD-G-95)57^ 4K*01N%.)$OR'[H2+.\[=G+X\9^V)
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MZRJ_@+PUR3Y86>V2HON%W'S1-OJ6SX:^:OP]L['& 5V'R< R9(%@Z).> W@
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MG1YO)X[7=L_.O5]N@20HH4.1&I"RK/WU>PX>)$A1LOR*DVQFIB8R'\#!>;\
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M7.8" A*:#U>J+-O:TV7*% WN++#7*Y=3;WW>UX&RK#5*D'T,]R5K8WQ8!,4
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M'';_,@4[B:J886T&L7,CP'148+='.I&P4/7533T*8D;/@!"AP<!#.#23H/_
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MZL7*5QY 5RQ5NVRH\NAJP[_>P87=!-B]I4XI\MF$QE'1((Z9??T YNSG6"[
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ML2<M?[\Y\--P^0Y_3/)I##_^!U!+ P04    " "U0WU5A!VH/%,#  !P#P
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M7Y"#DEY#VKFLA-C'5$%V\P]02P,$%     @ M4-]5?.$* 6!"   <E@  !4
M  !V=')S+3(P,C(Q,3(X7VQA8BYX;6S-G&MOVS84AK\/V'_@O"\;4,>Q#0Q+
MT+C(TJ0(EB9!DF(W#(4LT8XP60PH.7'^_4A)M$7RD%(J2A8*M K/>U[>GB/)
M2N7W'S:K"#UCFH0D/AF,#PX'",<^"<)X>3)8)T,O\<-P\&'V_7?O?Q@./^$8
M4R_% 9J_HO./GT[O%F'$I FZO;MAAQC]>G#(_Z#?*/$"&@9+/!SR9*;Z[YC_
M-?<2C%BG<7*\2<*3P6.:/AV/1B\O+P<OTP-"EZ/)X>%X].?GJWO_$:^\81@G
MJ1?[>("8_CC)&J^([Z79B$OIFSF-A,%TM.W+J. _#85LR)N&X\EP.C[8),&@
M&"(/U^A$R#>:OIC3^.CH:)1%MU)F%%JLM]-FJX=0OGZ41/@.+Q#_]\O=I3'[
M:,05HQBG5]X<1ZS++#U]?<(G@R1</458M#U2O(!](DJW-GQUCOCJC'_AJ_/C
MSGG49'A+CM(#2;W(S3@S/WVL6C?-!WWM:FEM0[YVN<JLQ'$'JUSJIOF@;S$-
M27 >!^T/7.W*U>#O4X]V@(K>6?,)M#]J8*@1;[IB1U*_>)/B.,"!Z)E[6\Z=
M6=?9R39SWGH37W*-^%6$4'TZ"7/-'!/L'RS)\RC (7.>C/G!D!]DLV _?#TC
M[.)Y.D]2ZOFI<,HF<3( 8VF8\K$KL9$\4)XO#97BA*RICY4>M!%\C>;1FQ9)
MVN-\:";35<2ZY;<%.!Y^N1^@,#!I9UD3^D<T_OM^M!NU/M-3*N^+1WTQ)'98
M,8U",?()NU@^I4-I1@M*5J9](!7+5ZQ&YG>,)!E*"3+DCEHG[B/QURL<IP_,
M4<$!"A73D$,-<"L;N:(-\#3!IDEGH@7QIOV"!JX_L:^;C%E9)2C3,]N'[ \:
MINR4>T96JW4<YC?;B4*#55-,RZ!IP!_HZ I$F[F)2'/.K @A.;9?1NV[1FHN
MLDPM*!?X6KS:Y_B>1*$?INPCZF=VPT%#+U*0,@N**4*"!OCJ=J[8-3J;P#4D
MS';M2 3VBZQECTB=595AU;6"5)-+^YC>4LSK [,ER,[T_&:7WBP6F"H(50N+
MR=J$#? UV[K"N+('$\X5B3,6'_HE <H5*)/L%_ :NTK>LOXR\.8< 7Z5:^<%
M<)DD:TQKEX%1#A<#('=7$IIY2X5AZJ=F><#I>I'DNO[6BGGKX8JQ;H^U;K1,
M0_48>FB_ADY9[P$?P47D+150P5@Q7276H!0D)U?<0Z8FR'7M;-N$>-M^V85W
M@50LGDRE)!,( KG=/8BX"!/?B_["'KU@+>JGQ J5\GA"4SEX4J%XNGYH =M7
M/;^ LG:/,O(HXF&4Q?OQ7,.TAZ3V@L-/.Y0$]<$'Z-<UW_D3]FK" 1W(N*1S
M1GG)M1W.]0[JD:[F::SG@O[1#NTGR+MAZ6W$EU)@YC7/[JC?_D+L(_LL;" >
MU"BT*QH'I$N.KBF'S*L(UW-V=!=8LR#BT7Z0#>\;J;G,,-&27*49\&J?Y/.8
MC?3U#B]#_@N:.+WV5BI6-DDQ35C2 &/(T!7%%F\3Q,:461Y!NQ#BL?T2;-TP
M4F^!97XAM<#7[-05O6>L>*@77;(/DYO?\2N(KT$C\:MI&@.L.+HE&#:W(PSE
M"(:+&,J"B$7[0+%IWTC-988X5N0RR*!75R1?A!&^7J_FVK,\4UCBMQQNC.[.
MS"VUFJ\=6$4N6.7-*&_O Z7 QI#JQ838W"EE+%6'KHA\\#:7 2N)<%'\5M*"
M9X568M6H;0RNP=DMQ?9.[$C;<@7?3(-D48]HK]IG\L;M@.K D"87A=6[JPJY
MC'U"GPC-!G"?LGOW,[)FUY#7,Q+ M]*U,J1JJ<AH7#-6?[>54Z<K>_U4.X@J
MDI3O4*9%A*)"CWA"'PJJ'A#DFW8,*BYKLEQB-?KIJM#.5Y@NPWCYB9*7]/&,
MK)Z\&+[9MRJEPC(H&Q<4Z.NVD&Q=V O(G"D*1RA0+D&%I@^U8M];\J9-@&H#
M3))KPN+;52V<!@%C,"G^N0IC/ 8KP:*3Z@#4-:X"P-5M#9@[L%> *4_P7P3>
MB0/$)>@F[L75PK:GY W+#]$/I,CL&SWW1_ZD)OF3FN1/6B%_TC;YDV\D?U*#
M_(<7TD_R)W7)G[R=_$D5^9-]DS^M2?ZT)OG35LB?MDW^]!O)G]8AGVU83\_Z
MT[KL3]_._K2*_>E>V#]CAS?T@;S$-O)U%<1]6>6*^IUG*\QK]K6(5[(TWGF<
M?RKFBAZ1#NPBQ#F\Y!;*=PD@XZI?QX1G'[%OZ"TESV&L 5='"K&N25T!KQBW
M0CW<1RWTH52-_^UC(2'K41&8]ABJ!,M>6,I!R0)K G3N^M2?/W:RGO=E"7C2
M%Q)G9_S<L)W3O>1=[UQ?2M%/]'FP1WBK.P:>X/45MIW=BT>[X*F][-0QOK<D
M2;WH[_#)^%L!FQ!"61&Z EJR;05KJ(=:<.N)&N*Y!#%-;Q[N6_<5 MZX Q;L
MI1P0?L"U_1+@-U.G%'L ]%"HF* <:O*M#R4C9U_ZH'L:O_-!E<ZR6VW>U ,Z
MP0T@]H63"2RKMM_VH&6V3QG_HJOH]I'$\/^=,86+R>CA!L2I9JZH,_B:R /E
MLZP59<V]^-\$QHTAU8LIDZ@J!8VP0P=OU&-_35DEC"?S!SY0A113N)B4'F[R
M+KUBYNQ->MC7^!X]))]EAX@LT'CRT_QG)$1[?I/>M#ND>D5E+%7E]AUZT*%]
M+*_) _7XMQ;>OZ[F) )>@;0HBJF!B@9\ GZN$#5;FR@U9<RN"2HB* _UX$5)
MVUZ16HLKTPJ(!;!&G_:9E3I6^ %CQ:246 -")2=7;$*F)BIU[4R&<;\<PKM
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M&1I*  #!LP( "0              @ $     97@R+3$N:'1M4$L! A0#%
M  @ M4-]52]("\C#%P  L&,   H              ( !04H  &5X.3DM,2YH
M=&U02P$"% ,4    " "U0WU5CJ-LH; C  "_N   "P              @ $L
M8@  9F]R;3@M:RYH=&U02P$"% ,4    " "U0WU5A!VH/%,#  !P#P  $0
M            @ $%A@  =G1R<RTR,#(R,3$R."YX<V102P$"% ,4    " "U
M0WU5\X0H!8$(  !R6   %0              @ &'B0  =G1R<RTR,#(R,3$R
M.%]L86(N>&UL4$L! A0#%     @ M4-]52^\%<SF!0  [3X  !4
M     ( !.Y(  '9T<G,M,C R,C$Q,CA?<')E+GAM;%!+!08     !@ & &T!
(  !4F      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
